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 Sudden cardiac arrest is a major public health challenge in the United States with very 
poor outcomes. Current advanced cardiac life support therapies with cardiopulmonary 
resuscitation, defibrillation, and medications save less than 5% of victims despite substantial 
evidence that many of these lives could be saved with improved resuscitation protocols including 
the expanded use of hypothermia.  Clinically, no effective treatment other than targeted 
temperature management is utilized. We have previously demonstrated that WIN55, 212-2 
(WIN55), a non-selective cannabinoid CB1/CB2 receptor agonist, induced hypothermia when 
administered immediately following resuscitation with significantly improved post-resuscitation 
myocardial and cerebral function and duration of survival. We further demonstrated that the 
hypothermia effect of WIN55 is mediated through CB1 receptors.  
However, the results of our previous studies indicated that the beneficial effect of WIN55 





hypothermic effect. The overall objective of this study is to determine if cardiac arrest causes 
mitochondrial dysfunction and increased plasma concentrations of TNFα, IL6 and IL10. 
Intramuscular Administration of SR141716A (CB1 antagonist) before ventricular fibrillation + 
cardiopulmonary resuscitation followed by infusion of WIN55 5 min after return of spontaneous 
circulation will prohibit the release of inflammatory mediators caused by cardiac arrest via the 
CB2 receptor. 
We explored the effects of cardiac arrest on mitochondria populations and heart whole 
tissue lysate proteomics utilizing the Weil Institute’s in vivo rat model of cardiac arrest and 
cardiopulmonary resuscitation. We have discovered that brain mitochondria are more sensitive to 
global ischemia compared to heart mitochondria. Additionally, complex I is the most sensitive 
electron transport chain complex to ischemic injury and is a major control point of the rate of 
oxidative phosphorylation following cardiac arrest and cardiopulmonary resuscitation. 
Preservation of brain mitochondrial activity and function during cardiac arrest may enhance 
outcomes and recovery.  
A recent article focusing on acute myocardial infarction was able to link S100A8 and 
S100A9 gene upregulation during ischemia and reperfusion and revealed this caused 
mitochondrial dysfunction in cardiomyocytes. S100A8 and S100A9 protein expression levels 
were upregulated in rat LV Apex epicardium whole tissue lysate from animals that experienced 
global ischemia reperfusion injury via cardiac arrest and cardiopulmonary resuscitation. Further 
studies are necessary to confirm S100A8 and S100A9 proteins increase expression in brain and 
heart tissue samples after cardiac arrest and cardiopulmonary resuscitation. 
Testing WIN55 as a possible pharmacologic tool, in vitro results indicated that WIN55 





of SR141716A (CB1 antagonist) before ventricular fibrillation + cardiopulmonary resuscitation 
followed by infusion of WIN55 5 min after return of spontaneous circulation. After treatment, 
plasma concentrations of TNFα, IL6 and IL10 were decreased at return of spontaneous 
circulation 4hrs. One possible mechanism to drive down proinflammatory cytokine release is 
binding CB2. WIN55 could be a novel pharmacologic tool against cardiac arrest as it can induce 
hypothermia and it has ant-inflammatory effects. Further studies are needed to determine 
mechanism of action for anti-inflammatory effects as peroxisome proliferator-activated receptors 








CHAPTER 1: Introduction and Literature Review 
 
I. Cardiac Arrest 
A. Epidemiology and Disease Spectrum 
Cardiac arrest (CA) is a major public health problem with substantial morbidity and 
mortality. It is the cessation of cardiac mechanical activity, as confirmed by the absence of signs 
of circulation (1). CA is characterized by severe and generalized ischemia that persists during the 
resuscitation efforts and reverses only after restoration of spontaneous circulation (ROSC) (2). 
An operational definition of sudden cardiac arrest (SCA) is unexpected CA that results in 
attempts to restore circulation (1). If resuscitation attempts are unsuccessful, this situation is 
referred to as sudden cardiac death (SCD). In the United States, any-mention sudden cardiac 
death (SCD) mortality in 2017 was 379, 133 (1). Over the past 5 decades, the strategy of 
cardiopulmonary resuscitation (CPR) has been focused on early defibrillation, better and more 
effective chest compression, and more recently, post-resuscitation management including 
therapeutic hypothermia. However, the current outcomes of CPR are disappointing, which yield 
a functional survival rate of only 8.2% (1). Circulatory failure and myocardial dysfunction 
resulting from CA largely contribute to morbidity and mortality after initially successful CPR 
(3). Out-of-hospital cardiac arrest (OHCA) is a significant cause of death and disability in adults 
with 356,461 reported “EMS-worked” cases per year in the United States (1). 
B. Ischemia Reperfusion Injury 
Ischemia is an imbalance between the oxygen demand of the tissue and the oxygen 
delivery that it receives.  Oxygen delivery could be simple diffusion or the heart delivering 
oxygen conductively (oxygen through blood flow). Whenever oxygen delivery does not match 
demand, technically it is ischemia. Ischemia is a condition where energy expenditure outpaces 
energy production. For aerobic cells ischemia is a critical change in the oxygen demand to 





interrelated factors, including a decrease in cellular adenosine triphosphate (ATP) levels, 
accumulation of hydrogen ions, calcium overload, and production of reactive oxygen species 
(ROS) (5). Cerebral and myocardial tissue suffers from IR injury even after successful CPR (6, 
7). The destructive effects of IR arise from the acute generation of ROS subsequent to 
reoxygenation, which inflicts direct tissue damage and initiates a chain of deleterious cellular 
responses leading to inflammation, cell death, and eventually organ failure (8). The cessation 
(ischemia) and restoration (reperfusion) of cerebral blood flow (CBF) after CA induce 
inflammatory processes that can result in additional brain injury (9). Post-cardiac arrest (post-
CA) ischemia induces neurodegeneration, cerebral edema and impaired cerebrovascular 
autoregulation within the brain (10). This phenomenon is reflected in 2004 epidemiological data 
that shows brain injury as the leading cause of death post-CA, accounting for 68% and 23% of 
OHCA and in-hospital cardiac arrest (IHCA) deaths (10). 
Post-arrest myocardial dysfunction includes the development of low cardiac output (CO) 
or ventricular systolic or diastolic dysfunction (7). The pathophysiology involves cardiovascular 
IR injury and cardiovascular toxicity from excessive levels of inflammatory cytokine activation, 
among other contributing factors (7). There is an almost instant inflammatory response where 
interleukins are produced by affected tissues and the endothelial cells of the local capillary 
vasculature (11). Chemical signaling results in white blood cells being attracted to affected areas 
and attaching themselves to the endothelial lining of the capillaries, resulting in capillary 
blockage and further ischemia (11). It is recognized that cells can be programmed to die by 
cellular signaling mechanisms via the processes of apoptosis and autophagy. 
C. Mitochondrial Dysfunction 
Neurologic and myocardial dysfunction after successful resuscitation is prominent and 





cardiomyocytes, two high energy-consuming organs, are enriched with mitochondria and are 
highly sensitive to IR injury (17). The central nervous system receives almost a third of the CO 
(9). Morbidity and mortality after initially successful CPR can be attributed to immediate and 
delayed effects of reperfusion in the central nervous and cardiovascular systems (18). The 
principal role of mitochondria is to generate cellular energy (ATP) by the mitochondrial electron 
transport chain (ETC) through oxidative phosphorylation (OXPHOS). An adequate amount of 
energy by mitochondria is crucial for neuronal excitability and survival. In addition, 
mitochondria are critically involved in the regulation of cell death via apoptosis, autophagy and 
necroptosis (14, 19).  
Mitochondrial dysfunction is one hallmark of IR injury, which induces neuronal death (9, 
20). During the ischemic phase, OXPHOS is inhibited by lacking oxygen, causing low levels of 
adenosine triphosphate (ATP) and  cellular acidification secondary to the diverging of glycolytic 
pyruvate to lactate (21). Upon reperfusion, the rapid re-establishment of OXPHOS induces 
several mitochondrial events such as ROS generation, H+ leaking, mitochondrial Ca2+ overload 
and the release of cell-death inducing protein cytochrome c (21).  
Ultrastructural and functional injury occurs early in and progresses during ischemia (22). 
Mitochondrial morphological dynamics are relevant to IR injury (23, 24). Under physiological 
conditions, the removal of damaged or dysfunctional mitochondria is mediated by mitophagy, a 
mitochondrial-selective subtype of autophagy that involves sequestration and subsequent fusion 
of mitochondrial contents with lysosomes containing degradative enzymes (25, 26). This process 
allows maintenance of mitochondrial homeostasis; however, in the context of major cellular 
stress like that of IR or heart failure, mitochondrial DNA leak out from damaged and necrotic 





as the damage-associated molecular patterns (DAMPs) that can activate several pro-
inflammatory pathways, such as toll-like receptor (TLR) on immune cells such as circulating 
neutrophils and macrophages, leading to the formation of inflammatory cytokines TNFα and IL6 
(Figure 1) (28-30). Mitochondrial DNA has also been shown to activate inflammasome 
complexes, which are responsible for recruiting active caspase-1 and converting pro-IL1β and 
proIL18 into their bioactive forms IL1β and IL18 (25, 31). Mitochondrial damage from 
cardiovascular events like IR thus appear to have major downstream effects on the development 





















Figure 1. Role of TLR in production of inflammatory mediators. Adapted from  (29). 
An experiment with a mitochondrial protective agent (SS31) demonstrates improved 
cardiac contractility and ejection fraction (EF) with lower levels of inflammatory cytokines 
TNFα and IL1β (32). Translational studies have yielded similar results. Levels of circulating 
cell-free mitochondrial DNA were found to be a more accurate prognostic marker in CA patients 
(33). Additionally, in the COMICA study, higher serum levels of mitochondrial injury marker, 
cytochrome c, were seen in post-CA patients compared to controls. Even higher levels were seen 
in non-survivors versus survivors (34). Neurological outcomes in post-CA have not been as 
extensively studied. However, anti-inflammatory studies in a rat model of cerebral IR yielded 





lower levels of oxidative stress following treatment (35). Based on these findings, further 
research into agents that can attenuate the pro-inflammatory pathway in mitochondrial 
dysfunction could prove to be crucial in improving functional and mortality outcomes associated 
with IR.  
Recognition of potential mitochondrial-driven pathology in IR has led to growing interest 
in investigating the relationship between mitochondrial injury and functional outcomes following 
SCA and IR. An imbalance in mitochondrial dynamics contributes to brain injury after cardiac 
arrest. Thus, targeting mitochondria is a promising neuroprotective strategy (36). Activation of 
the mitochondrial permeability transition represents a major mechanism of IR injury. A CB2 
receptor agonist (JWH133) protected mitochondria against IR injury and reduced apoptosis 
through inhibition of apoptotic protein released from the mitochondrial permeability transition 
pore (MPTP) (37). Administration of the cannabinoid agonist WIN 55,212-2 after hypoxia 
ischemia in fetal lambs reduces brain injury, diminishing both apoptosis and mitochondrial 
dysfunction (38).  
D. Post Cardiac Arrest Syndrome 
Whole-body ischemia and reperfusion due to CA and subsequent ROSC constitute post-CA 
syndrome (PCAS) (39). PCAS is a combination of post-cardiac brain injury, circulatory 
dysfunction, systemic IR response and persistent precipitating pathology proposed by Nolan et 
al. in 2008 (40-42). Binks et al. state PCAS can be divided into four phases 1) immediate post-
arrest (occurs in the first 20 minutes following ROSC 2) early post-arrest (occurs between 20 
minutes and 6 to 12 hours after ROSC) 3) intermediate (between 6 to 12 hours and 72 hours) 4) 
recovery (extends from 3 days and beyond) (43). Management of PCAS patients includes 
complex and multidisciplinary interventions. Early and intensive management should be focused 





PCAS is most notably characterized by profound IR injury. Due to CA being an extreme of 
shock states, oxygen delivery is dramatically reduced during an arrest event, leading to profound 
tissue hypoxia (44). Depending on the cause of the arrest and severity of PCAS, many patients 
will require multiple organ support (45). Treatment received during this post-resuscitation period 
influences the overall outcome significantly, particularly quality of neurological recovery (45). 
Although CA impacts all organ systems, its impact is most profound on the neurological system 
as brain tissue is exquisitely sensitive to lack of oxygen (46). Post-CA anoxic brain injury is a 
major cause of morbidity and mortality, and is responsible for two thirds of intensive care unit 
(ICU) deaths in the post-CA period (47). Post–CA myocardial dysfunction also contributes to a 
low survival rate after in- and out-of-hospital CA. However, preclinical and clinical evidence 
indicates that this phenomenon is both responsive to therapy and potentially reversible (10).  
Successful resuscitation from CA is usually characterized by the development of an IR 
syndrome of the body that may enhance cerebral and cardiac damage (41). The main determinant 
of this syndrome is a generalized activation of inflammatory reactions resulting in symptoms 
similar in many aspects to those of sepsis (48). Inflammatory responses play pivotal roles in the 
pathophysiology of cerebral and cardiac damage after CA/CPR (48-51). Systemic inflammation 
promotes disorders in the macro-circulation and micro-circulation and increases vascular 
permeability promoting protein extravasation and edema formation in the tissues, due to 
metabolic imbalance, leucocyte activation, endothelial toxicity and impairment of mitochondrial 
respiratory chain activity (40, 52).  
Management of the post–CA patient is complex, and addresses multiple key issues 
simultaneously: diagnosing and treating the etiology, minimizing hypoxic brain injury, 





cerebral ischemia induced by CA and followed by reperfusion triggers a multitude of processes 
that ultimately result in neuroinflammatory responses with activation of glial cells, release of 
proinflammatory cytokines, and delayed neuronal death (54). Levels of TNFα and IL6 were 
shown to be strongly associated with the severity of PCAS, mortality rate, and neurologic 
outcomes (54). The severity of this syndrome will vary with the duration and cause of CA (45). 
II. Role of Inflammatory Mediators in Cardiac Arrest 
A. Pro-inflammatory mediators (Tumor Necrosis Factor α and interleukin 6) 
Inflammatory responses play a pivotal role in the pathophysiology of brain and heart 
damage after CA/CPR, which leads to neuronal death, myocardial dysfunction, and apoptosis 
(55-57). Systemic and central nervous system (CNS) levels of various cytokines including tumor 
necrosis factor (TNF)α, interleukin (IL)1, IL6, IL8, IL10, and others are increased after CA (50, 
51). One definitive mechanism of cerebral IR injury is inflammation.  It is characterized by the 
activation of glial cells, influx of peripheral immune and inflammatory cells, high concentrations 
of ROS and release of pro-inflammatory mediators, including cytokines and adhesion molecules 
(58). The most studied cellular sources of ROS within the heart include cardiomyocytes, 
endothelial cells, and neutrophils (59). One function of cytokines is to change the physiological 
state of cells and the way they respond to environmental stimuli (60). TNFα induces 
inflammation, activates vascular endothelium, orchestrates the tissue recruitment of immune 
cells and promotes tissue destruction (60). Inflammation is a protective response of the host to 
infections and tissue damage, characterized by a series of reactions, including vasodilation and 
recruitment of immune cells and plasma proteins to the site of infection or tissue injury (61). 
Normally, inflammation is beneficial to the host and can be resolved in a timely manner; 
however, deregulated inflammatory responses can cause excessive or long-lasting tissue damage, 





release of DAMP molecules and cellular dysfunction in activated microglia and astrocytes 
contribute to ischemia-induced cytotoxic and pro-inflammatory cytokine generation, and 
ultimately to delayed death of neurons (58). TNFα has been shown to play an important role in 
the pathogenesis of neurological diseases (62). It has been demonstrated that the brain and innate 
immune system are engaged in bidirectional cross-talk.  The cerebral inflammatory cascade 
comprises an increase of neutrophil recruitment and peripheral macrophage infiltration, 
activation and migration of microglia, also known as brain macrophages and release of pro-
inflammatory stimuli within the brain. When an ischemic event occurs, the normally immune-
privileged brain environment collapses, DAMP molecules released by cellular injury can be 
recognized as invader to induce the activation of toll like receptors and triggers the activation 
process of nuclear factor ƙB (NFƙB), which is linked to the transcription of numerous 
proinflammatory genes (58).   
In the central nervous system, TNF is produced primarily by microglia and astrocytes in 
response to a wide range of pathological processes, including infection, inflammatory disease, 
ischemia and traumatic injury (63).This leads to neurologic damage. Cerebral injury is correlated 
to the abundant synthesis of inflammatory cytokines during CA and RES.  In the brain, cytokines 
are not only produced by the cells of the immune system, but are also expressed in resident brain 
cells including neurons and glia. Neuroinflammation can continue for days and months, which 
contributes to neurological damage that ultimately determines the impaired recovery following 
CA/CPR (58). Increasing evidence reveals that suppressing the inflammatory process facilitates 
neuroprotection and has the potential for use in the clinical treatment of cerebral IR damage 





Post-resuscitation myocardial dysfunction has been ascribed to post-ischemic stunning, 
the pathobiology of which has been well described in models of global and regional myocardial 
ischemia and reperfusion (64). Tumor necrosis factor (TNF) has been implicated in the 
pathogenesis of a number of cardiovascular diseases, including atherosclerosis, myocardial 
infarction, heart failure, myocarditis and cardiac allograft rejection, and vascular endothelial cell 
responses to TNF may underlie vascular pathology in many of these conditions (63). TNFα 
increases during the early post-resuscitation period and may play a role in post-resuscitation 
myocardial dysfunction (64). Niemann et al. show the time courses of LV systolic and diastolic 
dP/dt and TNFα are significantly negatively correlated. TNFα concentration is a statistically 
significant predictor of systolic dP/dt, with higher TNF concentrations being associated with 
decreased left ventricular systolic function (64). Hemodynamic effects of TNFα are 
characterized by decreased contractility, reduced EF, decreased systemic vascular resistance, 
hypotension, and biventricular dilation. TNFα is believed to exert its myocardial depressant 
effect by disrupting calcium homeostasis or calcium sensitivity and the normal myocardial 
contraction relaxation cycle (64). 
Cardiotoxicity is primarily attributed to TNF-induced cardiomyocyte apoptosis (60).The 
inflammatory response after ROSC is characterized by polymorphonuclear leukocyte activation, 
adhesion molecule expression, reactive oxygen species (ROS) production from inducible nitric 
oxide synthase (iNOS), and release of cytokines such as TNFα and interleukin 6 (IL6) (7). IL6 
represents a keystone cytokine in infection, cancer and inflammation, in which it drives disease 
progression or supports the maintenance of immunological reactions (65). An enormous 
repertoire of biological functions can be attributed to the cytokine IL6, establishing IL6 as a 





available during massive inflammation (66). Baseline IL6 was a good predictor of in-hospital 
mortality and poor functional outcome. It was associated with mortality in multivariable analysis 
(51). IL6 has context-dependent pro- and anti-inflammatory properties and is regarded as a 
prominent target for clinical intervention (65). 
Cytokine production is also altered by stress.  Increased production of TNFα, IL6 and  
IL1β contributes to the acute-phase reaction and hypermetabolic response that accompanies 
overwhelming infection , hemorrhage, injury and surgery (64). These stress-activated cytokines 
all have the potential to produce cardiac decompensation when in sufficiently high 
concentrations (64). The effects of stress-activated cytokines extend beyond the myocardium.  
B. S100A8 and S100A9 
S100A8 and S100A9, also known as myeloid-related protein 8 (MRP8) and MRP14 
respectively, are DAMPs that belong to the S100 family. Both are constitutively expressed in 
neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated 
upon the onset of trauma, infection, stress and other inflammatory processes (67-70). Under 
physiological conditions they can exist as homodimers, but under inflammatory states they 
preferentially form heterodimers with each other (S100A8/A9) because the heterodimeric 
structure confers increased resistance to the protease-rich environment of inflammation (71). 
Additionally, S100A8 and S100A9 contain a characteristic helix-loop-helix motif with charged 
amino acid residues, giving them a high affinity for divalent ions such as calcium (69).    
Therefore, they are calcium-binding proteins that have been implicated as key modulators 
in the development of inflammation (67). Together, these features allow S100A8 and S100A9 to 
achieve functional diversity both intracellularly and extracellularly (69). They are able to exhibit 
both intracellular and extracellular effects on various cells of the innate immune system and have 






Figure 2. Involvement of S100 proteins in stress and inflammation. Adapted from (70) 
Intracellular S100A8/A9 is best known for the ability to regulate trans endothelial 
migration of leukocytes (72). Transmigration is primarily achieved through extensive remodeling 
of the cytoskeletal structures which, in turn, is controlled by elevation of intracellular calcium 
levels and specific protein phosphorylation (72). As S100A8 and S100A9 are the major calcium-





induced S100A8/A9 complexes promote microtubule polymerization via direct interaction with 
tubulin (72).  
Extracellular S100A8 and S100A9 function primarily as DAMP molecules after being 
released from damaged or activated cells. The exact secretion mechanism remains unknown; 
however, it appears to require monocytic activation of both protein kinase C and the receptor for 
advanced glycation end products (RAGE) pathways (73, 74). Once released, S100A8/A9 exerts 
its effects through two different innate immune receptors: TLR4 and RAGE (67). Upon binding 
to TLR4 on phagocytes, S100A8/A9 triggers the MyD88-dependent pathway, where MyD88 
recruits and activates IL1R-associated kinases (IRAKs) and TNFR-associated factor 6 (TRAF6). 
This, in turn, causes a downstream signaling cascade, ultimately leading to loss of inhibition of 
transcription factors NF-kB and AP-1. These factors can then translocate the nucleus and induce 
expression of pro-inflammatory cytokines such as TNFα, IL6 and IL8 (Figure 3) (69). Similarly, 
binding to RAGE results in subsequent activation of JNK and JAK-STAT signaling (75). Effects 
are under investigation but appear to inhibit anaerobic glycolysis in myocardium in the setting of 
ischemia (76). Overall, S100A8/A9 serves as a key modulator in the early stages of inflammation 







Figure 3. S100A8/A9 effects through TLR4 (77). 
C. Anti-inflammatory mediators (interleukin 10) 
Anti-inflammatory cytokines, such as IL10, have been shown to inhibit the LPS-induced 
production of pro-inflammatory cytokines (78). IL10 is a secondary cytokine released by 
leukocytes or endothelial cells following stimulation by IL1β and TNFα (51). IL6 might also 
contribute to the regulation of inflammation by inducing IL10‑producing B regulatory (Breg) 
cells (66). Zhang et al show an elevated level of IL-10 attenuates LPS-induced activation of NF-
κB, JNK, ERK and p38MAPK, which results in reduced production of TNFα and IL6 (78). 
Understanding the role of IL10 in the regulation of metabolic processes is essential both for 
deciphering how IL10 acts to control inflammatory responses and for discovering key molecular 





described in TH2 cells where its expression accompanies that of the TH2 type cytokines IL4, IL5 
and IL13 (80).  
In the absence of IL-10 signaling, macrophages accumulate damaged mitochondria in a 
mouse model of colitis and inflammatory bowel disease, which results in dysregulated activation 
of the NLRP3 inflammasome and production of IL-1β (79). The absence of IL10 leads to ROS 
production from accumulated mitochondria (79). Various cell types can express IL-10, which 
makes IL10 regulation challenging (80). IL10 might act to reverse the metabolic program 
associated with inflammatory response (79). 
III. Cannabinoids 
A. Endocannabinoid System (ECS) 
The psychoactive properties of marijuana have been known for thousands of years, 
however, the biological basis of the effects of marijuana and its bioactive ingredients, 
collectively called cannabinoids, has unfolded in the last few decades (81, 82). Since 1998, the 
use of cannabis for medical purposes has become legal in 29 states (according to state, but not 
federal law) in the USA, and numerous countries have also opted to legalize marijuana for 
medicinal use (83). Cannabinoid compounds are being extensively studied for therapeutic 
potential. Although there is an abundance of information on the role of cannabinoids in the 
central and peripheral nervous systems, their role in the cardiovascular system is more complex 
(84). Cannabinoids and their synthetic and endogenous analogs are best known for prominent 
psychoactive properties, however, their cardiovascular effects were recognized as early as the 
1960’s (85). Cannabinoids are highly lipophilic molecules that have been shown to alter the 
functional activities of immune cells in vitro and in vivo.  The term “exogenous cannabinoid” has 





synthesized in the laboratory (86). WIN55,212-2 (WIN55) is an exogenous cannabinoid (Figure 
4). 
 
Figure 4. WIN55 is a full agonist for CB1 and CB2 (87) 
Cannabinoids modulate inflammation through multiple pathways (88). They have been 
reported to have immunosuppressive activity and alter macrophage functions (89). It has been 
reported that, under pathological conditions, cannabinoids can avoid mitochondrial dysfunction, 
thus inhibiting apoptotic signaling (38) .Cannabinoids were shown in vivo and in vitro, to exert 
their immunosuppressive properties through 4 main pathways: induction of apoptosis, inhibition 
of cell proliferation, inhibition of cytokines, and chemokine production and induction of 
regulatory T cells (tregs) (90). Distinct phytocannabinoids may activate immune cells by 
receptor-mediated as well as by non-receptor mediated modes (91).Cannabidiol inhibits IL1, 





enhances production of the Th2-associated cytokines, IL4 and IL10 (90). The ECS, which 
comprises specific cannabinoid receptors, endogenous ligands (endocannabinoids), and synthetic 
and degradative pathways, is a new therapeutic target in a variety of disorders, such as 
inflammation and tissue injury, including the cardiovascular system (37). 
B. Cannabinoid Receptors 
Endocannabinoids (eCBs) act locally in a paracrine or autocrine manner by activating 
cannabinoid receptors (83). The endocannabinoid signaling system has emerged as an important 
target for therapeutic drug development, although the design of receptor-selective ligands has 
remained a challenge (92). Endocannabinoids may limit hepatic injury by modulating the 
expression of adhesion molecules and the infiltration and activation of inflammatory cells by 
CB2 dependent mechanisms, which is consistent with the emerging role of CB2 receptors in 
regulating microglial cell function and neuroinflammation (8). The discovery of cannabinoid 
receptors that mediate the action of THC and synthetic cannabinoids, precipitated the search for 
the endogenous ligands that bind these receptors. Arachidonoyl ethanolamide or anamide (AEA) 
and 2-arachidonoylglycerol (2-AG) represent the primary endogenous ligands that bind and 
activate CB1 and CB2 (91). 
These cannabinoid receptors belong to the G-protein coupled receptor family and play a 
key role in downstream intracellular regulation of apoptosis and inflammation (82). Both 
receptors have seven transmembrane domains, are coupled to inhibitory G proteins, and are 
linked to signaling cascades that may involve adenylyl cyclase and cAMP, mitogen-activated 
protein (MAP) kinase, and the regulation of intracellular calcium (91). Cannabinoid receptors 
signal via Gi/o-protein-dependent pathways to inhibit adenylyl cyclase and modulate ion-channel 
function, but also activate mitogen-activated protein kinases (p44/42 MAPKs, p38, ERK, and 





(Figure 5) (83). Saroz et al. recently reported CB2 activation induces simultaneous Gαi and Gαs 
(G protein-stimulating adenylate cyclase) coupling, which produces a delayed cAMP flux in 
human primary leukocytes (93, 94). The cannabinoid system with its receptors (CB1 and CB2), 
provides neuroprotection against cerebral and spinal cord ischemia-reperfusion (IR) injuries (95). 
During ischemic injury, endocannabinoids accumulate, cannabinoid receptors are up-regulated, 
and treatment with cannabinoid agonists (either endocannabinoids or 
phytocannabinoids/synthetic cannabinoids) protects neurons against damage resulting from 







Figure 5. Cannabinoid receptor signaling (a) The adenylate cyclase (AC) pathway. Gαi 
signaling downregulates the pro-inflammatory immune response via adenylate cyclase. CB2 
couples predominantly to Gαi/o, resulting in adenylyl cyclase inhibition (b) The mitogen-activated 
protein kinase (MAPK) pathway. CB2 βγsubunit mediated activation of the MAPKs extracellular 
regulated kinase (ERK1/2), p38 and janus-kinase (JNK)(86, 97). The CB2 receptor is coupled 
with Gαi/o and Gαq (G protein-activating phospholipase C and G protein-increasing cytosolic Ca
2+) 
(94). 
In the cardiovascular system, cannabinoid receptors are located in the myocardium, 





and CB2 receptor signaling modulate remote ischemic preconditioning-induced cardio protection 
(98). Endocannabinoids overproduced during various forms of IR injury have been proposed to 
protect against myocardial IR injury and to contribute to the ischemic preconditioning effect of 
endotoxin, heat stress, or brief periods of ischemia, while these lipid mediators may also mediate 
the cardiovascular dysfunction in these pathologies (99).   
In a whole animal model of myocardial IR injury induced by coronary 
occlusion/reocclusion in anesthetized mice, the protective role of CB2 but not CB1 receptor 
activation was determined (8). Cannabinoid receptor 2 could potentially mediate protection 
against the four phases after resuscitation (thought to occur depending on the degree and duration 
of organ ischemia): 1. first 24hours after the event-a microcirculatory dysfunction from the 
multifocal hypoxia leads to rapid release of toxic enzymes and free radicals into the 
cerebrospinal fluid and blood; 2. 1 to 3 days- cardiac function and systemic function improve, 
but intestinal permeability increases predisposing the patient to sepsis syndrome leading to 
multiple organ dysfunction syndrome; 3. Days after cardiac arrest-a serious infection may occur, 
and the patient declines rapidly, and; 4. The patient eventually dies (48). “Myocardial stunning” 
classically defined as temporary mechanical dysfunction persisting after episodes of ischemia 
and reperfusion with the absence of irreversible histological damage is also responsive to 
therapeutic initiatives, namely inotropic therapy or even antioxidants or calcium antagonists for 
implementing prevention strategies (100).  
In addition to the cell-surface cannabinoid receptors, there is growing evidence that the 
intracellular peroxisome proliferator-activated receptors (PPARs) are cannabinoid targets (101). 
There are other non-CB1/CB2 receptors—such as GPR55, GPR119 and TRPV1 that are 





endocannabinoids (102). PPARγ is a nuclear hormone receptor that regulates gene expression as 
a ligand-activated transcription factor and, in the central nervous system, is expressed on 
oligodendrocytes and astrocytes as well as neurons in multiple brain areas (103). WIN55 has 
been reported to reduce inflammation in murine brain ECs through PPARγ, independent of CB1 
and CB2. This mechanism needs further exploration (104) as nuclear transcription factors play an 
important role in the regulation of initiation and resolution of the inflammatory process (Figure 
6) (105). Direct binding of PPARs and the indirect effect of these receptors stimulate production 
of antioxidant enzymes and inhibit NFkβ (105). Activated PPARγ with endogenous or synthetic 
ligands can not only directly combine with the p50/p65 dimer and form a new complex that 
downregulates the NFkβ signaling pathway but also upregulate the expression of IkBα and 






Figure 6. Cross-talk between PPARs and TLRs and NFkβ. Adapted from (105) 
C. Anti-inflammatory properties of CB2 
The first record of medical application of the strong anti-inflammatory effect of cannabinoids 
comes from the world’s oldest pharmacopoeia, which was found in China (82). 
Endocannabinoids mediate inflammation by regulating cytokines at different steps throughout 
the inflammatory response (88). CB2 receptors are expressed mostly in the immune system, 
including the thymus, spleen, lymphatic nodes, and circulating leukocytes, where they mediate 
cytokine release (82). Levels of CB2 expression varies among different immune cell populations, 
with B lymphocytes expressing the highest levels followed by macrophages, monocytes, natural 





been the identification of low levels of CB2 receptor expression in tissues previously thought to 
be devoid of these receptors. These include specific regions of the brain ( 
Figure 7), spinal cord and dorsal root ganglia, neurons in the myenteric and submucosal 
plexus of the enteric nervous system, in myocardium or cardiomyocytes (Figure 8), human 
vascular smooth muscle and endothelium, activated hepatic stellate cells, Kupffer cells, in 
reproductive organs/cells, colonic epithelial cells, bone, mouse and human exocrine and 
endocrine pancreas, and in various human tumors (107). An interesting biologic property of CB2 
receptors is their high inducibility, with CB2 mRNA levels often increasing as much as 100-fold 
following nerve injury or during inflammation (108). 
 
Figure 7. Brain CB2 expression and function and association with neuropsychiatric and 






Figure 8. Mapping of cannabinoid-sensitive receptors and eCBs in the heart (97). 
A large body of preclinical research demonstrates the effectiveness of cannabinoids in rodent 
models of acute and chronic inflammatory pain, as well as neuropathic pain (88). The 
inflammatory response to insult must be tightly regulated in order to minimize damage to healthy 
tissues.  Thus, in addition to proinflammatory cytokines, active immune cells produce and 
release anti-inflammatory mediators, including IL10, which are regulated by the 
endocannabinoid system (88). Accumulating evidence supports the development of selective 
CB2 receptor agonists for the management of acute tissue injury associated with inflammation 
(such as myocardial infarction, stroke, or organ transplantation) (83). Since CB2 activation 
dampens inflammatory responses in the absence of psychotropic effects, it has the potential to 
serve as a molecular target for attenuating inflammation linked to pathogenic disorders (91). 
Consistent with the protective role of CB2 receptor activation, CB2 





induced tissue damage and proinflammatory phenotype (8). Selective activation of the CB2 
receptor a few minutes before reperfusion markedly improves myocardial infarction (110). 
Mechanistic investigations reveal that the protective effect of CB2 receptor may ascribe to 
reduction of cardiac leukocyte recruitment, reduction of superoxide generation, or increase of 
ERK1/2 and STAT-3 phosphorylation (37). CB2 signaling in the heart and vasculature may 
activate cardioprotective mechanisms and limit inflammation (Figure 9) (107). Evidence from in 
vitro and in vivo models suggests that CB2 activation might reduce atherosclerotic inflammation 
(110). CB2 receptor stimulation limits hepatic injury by decreasing the expression of ICAM-1, 
CVAM-1, neutrophil infiltration, TNFα, chemokine (MIP-1α and MIP-2) levels, and lipid 
peroxidation. The decrease in lipid peroxidation can be secondary to the decrease of 
inflammatory cell infiltration and activation (8). However, the lack of highly selective CB2 
receptor antibodies limits interpretation of some studies. Thus, the use of stringent negative 
controls is crucial for the correct detection and quantification of protein targets (88).





Collectively, a number of studies suggest that exogenous cannabinoids elicit a shift in the 
cytokine expression profile from that which is Th1 proinflammatory to one that is Th2 anti-
inflammatory and that the CB2 receptor may be linked to this effect (111). It has been observed 
that the CB2 agonist HU-308 attenuated hepatic ischemia/reperfusion injury by decreasing levels 
of TNFα, MIP-1α and MIP-2 in serum and liver homogenates (112). Cannabinoid CB2 receptor 
knockout (CB2 
-/-) mice are fertile, care for their offspring, and have a similar phenotype as their 
wild-type littermates (8), which shows CB2 knockout is not lethal.  
Possible mechanisms between systemic inflammation and hemodynamics have not been fully 
characterized but direct effects of inflammatory mediators on the contractility of the myocardium 
and vascular smooth muscle have been suggested (113). Though WIN55 has been demonstrated 
to have anti-inflammatory and anti-oxidative effects in inflammatory or ischemia diseases 
independent of its hypothermic effects, previous studies could not exclude other effects (114). 
Recent studies have indicated that activation of CB2 leads to an anti-inflammatory response; 
therefore, the beneficial effects of WIN55 following resuscitation may be related to both CB1 
and CB2 receptor activation. 
IV. Research Objectives 
Cannabinoids produce hypothermia in normal rats through the activation of central CB1 
receptors. WIN55, the nonselective cannabinoid CB1/CB2 receptor agonist, produced 
hypothermia in a dose-dependent manner when injected intramuscularly. The body temperature 
reduced from 37 to 34oC, 60 to 180 mins post injection and hypothermia was maintained up to 5 
hours. The effect was completely blocked by the selective CB1 antagonist SR141716A (115, 
116). CB2 receptor ligands have potential therapeutic applications as immunomodulators for the 






Figure 10. WIN55, 212-2 can be coupled to either CB1 or CB2 with different functional 
consequences.  
The effects of WIN55 were investigated initially in our rat model of CA and CPR. WIN55 
was selected based on the following reasons: 1) the described hypothermia effect of CB1 agonist 
is convincing and well documented, 2) it is highly selective for cannabinoid receptors and 
interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in 
thermoregulatory areas of the central nervous system and therefore decreases body temperature 
via a central mechanism (119), 4) It has been shown to be neuroprotective (120) and 5) It has 
been demonstrated in both mice and rats that the CB2 receptor activation effects of WIN55 have 
significant anti-inflammatory effects (121-123). CB2 expression has been demonstrated in cardiac 
myocytes and endothelial and smooth muscle cells of coronary arteries (84).  
Hypothesis: Cardiac arrest will cause mitochondrial dysfunction and increase plasma 
concentrations of TNFα, IL6 and IL10. IM Administration of SR141716A before VF+CPR 
followed by infusion of WIN55 5 min after ROSC will prohibit the release of inflammatory 








CHAPTER 2: Materials and Methods 
 
I. Reagents 
Lipopolysaccharide (LPS), sodium chloride (NaCl), (R)-(+)-WIN55,212-2 mesylate salt, 
polysorbate 80, dimethyl sulfoxide, DTT (Pro#1000748546), iodoacetamide (Pro#122270250), 
LC-MS/MS grade water, methanol, acetonitrile and common laboratory chemicals were 
purchased from Sigma Aldrich (St. Louis, MO). Pierce Trypsin Protease, MS grade (Pro# 
90057), Pierce BCA Protein Assay Kit (Pro# 23250) and Formic Acid Optima LC/MS (A11-50) 
were purchased from Fisher Scientific (Waltham, MA). A TMT10plex Isobaric Label Reagent 
Set plus TMT11-131C Label Reagent (A34808) was purchased from Thermo Scientific 
(Rockford, IL). Dulbecco’s Modified Eagle Medium (DMEM), 100x Penicilin/Streptomycin and 
1M HEPES were obtained from Life Techonologies, Gibco (Waltham, MA). Heat inactivated 
Fetal Bovine Serum (FBS) was from Atlanta Biologicals (Flowery Branch, GA). CB1 receptor 
antagonist SR141716A and (+)-WIN55,212-2 (mesylate) were purchased from Cayman 
Chemicals (Ann Arbor, MI). 
II. In vivo-Mitochondria 
Guanghui Zheng performed surgical technique, Xianfei Ji performed mitochondrial isolation 
and measurement and helped draft manuscript, Jeremy Thompson trained Xianfei Ji and Jennifer 
Bradley on all mitochondrial techniques, Rabiya Shabnam ran ETC assay, Jennifer Bradley 
analyzed all data and drafted manuscript and Qun Chen, Edward Lesnefsky and Wanchun Tang 
reviewed data and manuscript drafts. This study was approved by the Institutional Animal Care 





accordance with the Guide for the Care and Use of Laboratory Animals and the ARRIVE 
guidelines. 
Animal Preparation 
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by 
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-
gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). End-tidal 
CO2 (ETCO2) was continuously monitored with a side-stream infrared CO2 analyzer (Capstar-
100 Carbon Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II electrocardiogram 
(ECG) was monitored continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, 
USA) inserted into the descending aorta measured arterial pressure. A thermocouple microprobe 
(9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein 
measured blood temperature. Another PE-50 catheter advanced into the right atrium measured 
right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) 
advanced into the right atrium was utilized to advance a pre-curved guidewire into the right 
ventricle to induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated 
surgical board. ECG, aortic and right atrial pressures, ETCO2, and blood temperature were 
continuously recorded on a personal computer–based data acquisition system supported by 
WINDAQ software (DATAQ, Akron, OH).  
Experimental Procedures 
Animals were randomized into 4 groups (n=6 each group): 1) Sham (underwent surgery, no 
VF or CPR), 2) VF (VF only for 8 min), 3) VF+CPR (VF 8 min + CPR 8 min, no defibrillation) 
and 4) Return of Spontaneous Circulation (ROSC 1 hr) (VF 8 min, CPR8 min, defibrillation, and 





of 0.60 mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then 
induced with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the 
right ventricular endocardium. Current flow continued for 3 min to prevent spontaneous 
defibrillation. After 8 min of untreated VF, precordial chest compressions, together with 
mechanical ventilation, were initiated using a pneumatically driven mechanical chest 
compressor. Precordial chest compressions were maintained at a rate of 200/min and 
synchronized to provide a compression/ventilation ratio of 2:1 with equal compression-relaxation 
for 8 min. Defibrillation was attempted with up to three 4-J counter shocks. ROSC was defined 
as the return of supraventricular rhythm with a mean aortic pressure (MAP) above 50 mm Hg for 
5 min. 
 
Figure 11. In vivo-Mitochondria Experimental Protocol-N=6 for each group. Sham is time 
zero control. 
Cardiac mitochondria were isolated by a method previously described with slight 
modifications (124, 125). Hearts were removed and placed into buffer A [100 mM KCl, 50 mM 





mM ATP, pH 7.4] at 4°C. Cardiac tissue was finely minced and placed in buffer A containing 
0.2% bovine serum albumin (BSA) and homogenized with a polytron tissue processor 
(Brinkman Instruments, Westbury, NY) for 2.5 s at a rheostat setting of 14. The polytron 
homogenate was centrifuged at 2,200 rpm for 10 min, supernatant was saved for isolation of 
subsarcolemmal mitochondria (SSM), and the pellet was washed. Combined supernatants were 
centrifuged at 5,000 rpm for 10 min to sediment SSM. Interfibrillar mitochondria (IFM) were 
isolated by incubation of skinned myofibers, obtained after polytron treatment (2.5 sec at a 
setting of 14), with 5 mg/g (wet weight) trypsin for 10 min at 4°C.  SSM and IFM were washed 
twice and then suspended in 100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA. Mitochondrial 
protein concentration was measured by the Lowry method using BSA as a standard (125).  
Brain mitochondria were isolated by a method previously described with slight modifications 
(126). Brain (cerebrum) was rapidly removed and homogenized at 4οC in 10ml of isolation 
buffer B (215mM mannitol, 75mM sucrose, 20 mM HEPES, 1mM EGTA, pH 7.4) containing 
5mg of the bacterial protease type VIII (Subtilsin A). Brain homogenates were brought to 30 ml 
and then centrifuged at 12,000 rpm for 10 min. The pellet was resuspended in 10 ml of buffer C 
(buffer B+1mg/ml bovine serum albumin) and centrifuged at 2,420 rpm for 10 min. The 
mitochondrial pellet was resuspended in 10 ml of buffer C and centrifuged at 2,420 rpm for 10 
min. Combined supernatants were centrifuged at 9,000 rpm for 10 min. The pellet was then 
resuspended in 3 ml buffer C, and centrifuged at 9,000 rpm for 10 min. The pellet was 
resuspended in 2 ml buffer B, and centrifuged at 9,000 rpm for 10 min. Finally, the 






Oxygen consumption in mitochondria was measured using a Clark-type oxygen electrode at 
30°C as previously described (127, 128) using glutamate (20 mM) (complex I substrate), 
succinate (20 mM) (complex II substrate),  plus 7.5 mM rotenone and N,N,N’,N’ tetramethyl p-
phenylenediamine (TMPD; 1 mM)-ascorbate (10 mM) (complex IV substrate) + rotenone 
(Figure 12). Maximal ADP-stimulated respiration (2 mM ADP) was determined. Mitochondria 
were used within 6 hrs after isolation.  
 
Figure 12. Mitochondria Electron Transport Chain Complex substrates and inhibitors. 
Adapted from (22) 
Enzyme activities were measured spectrophotometrically in detergent-solubilized frozen-
thawed mitochondria using previously described methods (129): NADH-ubiquinone 
oxidoreductase, rotenone- sensitive (complex I=340nm), NADH-ferricyanide reductase 
(NFR=340nm); succinate-ubiquinone oxidoreductase, thenoyltrifluoroacetone sensitive (complex 
II=600nm); ubiquinol-cytochrome c oxidoreductase, antimycin A sensitive (complex III=550 





final protein concentration of 1 μg/μl in 0.5% cholate in MSM/EDTA buffer, pH 7.4 (220 mM 
mannitol, 70 mM sucrose, 5 mM MOPS, 2 mM EDTA) (130). 
Calcium retention capacity (CRC) was used to assess calcium-induced MPTP opening as 
previously described (131) in mitochondria (125 μg/ml) incubated in medium containing 150 
mM sucrose, 50 mM KCl, 2 mM KH2PO4, 5 mM succinate, in 20 mM Tris·HCl, pH 7.4, by 
sequential pulses of 5 nmol calcium. Extramitochondrial Ca2+ concentration was recorded with 
0.5 μM calcium Green-5N (Life Technologies City State), and fluorescence monitored with 
excitation and emission wavelengths at 500 and 530 nm, respectively (131). The calcium 
retention capacity CRC assay measures the susceptibility to opening of the permeability 
transition pore; and is performed in a non-acidic environment.   
III. In vivo-Proteomics 
Fenglian He and Christine Moore performed surgical technique, Gea-Ny Tseng performed 
tissue lysate preparation and Poochon Scientific LLC performed proteomic analysis. Jennifer 
Bradley reviewed proteomic results focusing on S100A8/A9 expression (132) and found it 
increased within LV Apex Epicardium following CA and CPR. This study was approved by the 
Institutional Animal Care and Use Committee of Virginia Commonwealth University. Animal 
care and handling were in accordance with the Guide for the Care and Use of Laboratory 
Animals and the ARRIVE guidelines. 
Animal Preparation 
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by 
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-
gauge cannula (Abbocath- T; Abbott Hospital Products Division, North Chicago, IL). ETCO2 





Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored 
continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the 
descending aorta measured arterial pressure. A thermocouple microprobe (9030-12-D-30, 
Columbus instruments, Columbus, OH, USA) inserted into the left femoral vein measured blood 
temperature. Another PE-50 catheter advanced into the right atrium measured right atrial 
pressure. A 3F catheter (Model C-PMS-301J; Cook Critical Care, Bloomington, IN) advanced 
into the right atrium was utilized to advance a pre-curved guidewire into the right ventricle to 
induce VF. Aortic blood temperature was maintained at 37°C ± 0.5°C by a heated surgical board. 
ECG, aortic and right atrial pressures, ETCO2, and blood temperature were continuously 
recorded on a personal computer–based data acquisition system supported by WINDAQ 
software (DATAQ, Akron, OH).  
Experimental Procedures 
Animals were randomized into 3 groups: 1) Sham (underwent surgery, no VF or CPR) (n=4), 
2) CPR (VF 8 min + CPR 8 min, defibrillation and ROSC) (n=4), 3) Norm (nothing done to 
animal) (n=3) (Figure 13). Mechanical ventilation was established at a tidal volume of 0.60 
mL/100g of body weight, a frequency of 100 breaths/min, and FiO2 of 1.0. VF was then induced 
with a progressive increase in 60-Hz current to a maximum of 3.5 mA delivered to the right 
ventricular endocardium. Current flow continued for 3 min to prevent spontaneous defibrillation. 
After 8 min of untreated VF, precordial chest compressions, together with mechanical 
ventilation, were initiated using a pneumatically driven mechanical chest compressor. Precordial 
chest compressions were maintained at a rate of 200/min and synchronized to provide a 





was attempted with up to three 4-J counter shocks. ROSC was defined as the return of 
supraventricular rhythm with a MAP above 50 mm Hg for 5 min. 
 
Figure 13. In vivo-Proteomics Experimental Protocol 
Measurements 
Once ROSC was reached Christine Moore or Dr. Tseng removed the heart for further 
analysis. Samples sent to Poochon Scientific were labeled Left Ventricle Apex epicardial 






Figure 14. LV Apex Epi- Samples sent to Poochon Scientific for further analysis were labeled 
LV Apex Epi from Dr. Tseng’s laboratory. Adapted from (133). 
General Protocol of protein lysate preparation performed by Dr. Tseng’s laboratory 
RIPA buffer: 20mM Tris-HCL pH7.4, 150mM Na\Cl, 1mM EDTA, 1% Triton-X100, 1% 
sodium deoxycholate, 0.1% SDS with freshly added PMSF to 1mM and with freshly added 
aprotinin and leupeptin to 5ug/ml was prepared just before use. The left ventricular (LV) apex 
was removed and placed in RIPA on ice for 10 min before homogenizing. Tissue was kept on ice 
during homogenization until tissue was liquified. Then liquified tissue lysate was centrifuged at 
13,000 rpm for 3min at 4°C. Clear supernatant was transferred to new clearly labelled tubes for 
shipment to Poochon Scientific (134). 





Tissue lysate samples were thawed at room temperature and a precipitation (cloud) was 
observed. 20 µl of 10% SDS was added to the sample and heated at 95°C for 10 minutes. After 
treatment the lysate became clear. Protein concentration of supernatant was determined by a 
BCA™ Reducing Reagent compatible assay kit from Thermo Scientific (Rockford, IL). The 
BCA Protein Assay is a popular method for colorimetric detection and quantitation of total 
protein (135). The assay was read at an optical density (OD) of 562nm. One major advantage of 
the BCA assay is that it produces a linear response curve. This response curve allows accurate 
determination of unknown protein concentrations and provides a higher dynamic range than 
other standard assays (135). 
TMT-11plex labeling performed by Poochon Scientific 
100 µg of protein lysate was taken from each sample for in-solution trypsin digestion. 
Predigestion was ran along with digested samples on SDS-PAGE and stained to check digestion 
efficiency. Isobaric labeling was performed using a commercial TMT10plex Isobaric Label 
Reagent Set plus TMT11-131C Label Reagent kit according to the product manual and samples 
were labeled as described in Table 1. The 11 labeled peptide mixture was then dried in a vacuum 











Table 1. Summary of 11 cell pellet sample labeling 
 
    Sample Label                   Description              TMT-tag        TMT Quantification (ratio)           
 
S1                                Norm_1                  126                         126/131 
S2                                Norm_2                  127C                     127C/131 
S3                                Norm_3                  127N                     127N/131                      
S4                                CPR_1                    128C                     128C/131 
S5                                CPR_2                    128N                     128N/131 
S6                                CPR_3                    129C                     129C/131 
S7                                CPR_4                    129N                     129N/131 
S8                                Sham_1                   130C                    130C/131 
S9                                Sham_2                   130N                    130N/131 
S10                              Sham_3                   131                        131/131 
S11                              Sham_4                   131C                    131/131-C 
 
 
Fractionation of labeled peptides by basic reversed phase UHPLC 
Dried labeled peptides were resuspended in 10 mM TEABC. Labeling efficiency was 
determined before fractionation by analysis of a small sample aliquot (1%). A minimum labeling 
efficiency of 95% was required. The fractionation of TMT-10plex labeled peptide mixture was 
carried out using an Agilent AdvanceBio Column (2.7 µm, 2.1 x 250 mm) at Solvent A (10 mM 
TEABC, pH 8.0) and an Agilent UHPLC 1290 system. Separation was performed by running a 
gradient of Solvent B (10 mM TEABC, pH 8.0, 90% ACN) and Solvent A (10 mM TEABC, pH 
8.0) at a flow rate 250 µL/min. Elute fractions were collected into a 96-well plate using a 1260 
series auto-sample fraction collector. The 96 elute fractions were further combined into 24 
fractions according to collection time (e.g. Ax/Cx/Ex/Gx, and Bx/Dx/Fx/Hx, A/B/C/D/E/F/G/H 
represents column, x represents row 1 through row 12) for LC/MS/MS analysis. 





LC/MS/MS analysis was carried out using a Thermo Scientific Q-Exactive hybrid 
Quadrupole-Orbitrap Mass Spectrometer and a Thermo Dionex UltiMate 3000 RSLCnano 
System. Each peptide fraction from a set of 24 fractions was loaded onto a peptide trap cartridge 
at a flow rate of 5 μL/min. Trapped peptides were eluted onto a reversed-phase 20 cm C18 
PicoFrit column (New Objective, Woburn, MA) using a linear gradient of acetonitrile (3-36%) in 
0.1% formic acid. The elution duration was 110 min at a flow rate of 0.3 μL/min. Eluted peptides 
from the PicoFrit column were ionized and sprayed into the mass spectrometer, using a 
Nanospray Flex Ion Source ES071 (Thermo) under the following settings: spray voltage, 1.8 kV, 
Capillary temperature, 250°C. 24 fractions were analyzed sequentially. The Q Exactive 
instrument was operated in the data dependent mode to automatically switch between full scan 
MS and MS/MS acquisition. Survey full scan MS spectra (m/z 300−1800) was acquired in the 
Orbitrap with 70,000 resolutions (m/z 200) after accumulation of ions to a 1 × 106 target value 
based on predictive automatic gain control (AGC). Dynamic exclusion was set to 20 s. The 15 
most intense multiply charged ions (z ≥ 2) were sequentially isolated and fragmented in the 
octopole collision cell by higher-energy collisional dissociation (HCD) using normalized HCD 
collision energy 28% with an AGC target 1×105 and a maximal injection time of 100 ms at 
17,500 resolutions. MS Raw data files (24 files from 24 fractions) were searched against the 
Rattus norvegicus (Rat) protein sequences database obtained from UniprotKB website using 
Proteome Discoverer 1.4 software (Thermo, San Jose, CA) based on the SEQUEST and 
percolator algorithms. False positive discovery rates (FDR) was set on 5%. A Proteome 
Discoverer Report was generated containing all assembled proteins with peptides sequences and 





TMT-tag based quantification was used to determine the relative abundance of proteins 
identified from each set of 11 samples using one TMT-10plex. The TMT-Tag-131 was used as 
the common denominator for calculation of the ratio (e.g. A1-TMT-tag-126 versus sample 11-
Tag131). Relative abundance of proteins was normalized based on the sum of ratios (Figure 15 
and Figure 16).
 
Figure 15. Poochon Scientific Schematic of Experimental Workflow. One TMT set labeled 





labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC, 
nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization 
and data analysis. 
 
Figure 16. Poochon Scientific Schematic of Experimental Workflow. One TMT set labeled 
11 samples. Procedures included preparation of lysates, trypsin digestion, TMT-ll plex of 
labeling of tryptic peptides, fractionation of labeled peptides by basic reverse-phase UHPLC, 
nano-LC-MS/MS analysis on a Q-Exactive mass spectrometer, database search, normalization 
and data analysis. 
Analysis performed by Jennifer Bradley 
Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes and biological 
pathways, was used to map pathways from proteins identified. NCBI accession numbers (136) 
(4,997) were converted to Kegg (137) (3,195). One KEGG pathway was identified to have been 
significantly regulated by CA/CPR (138). NCBI terms were converted to Go terms by Biological 
DataBase network with p values obtained by Poochon Scientific for Revigo analysis. Revigo 





IV. In vitro-WIN55 
Yanyan Wang trained Jennifer Bradley on in vitro techniques, Jennifer Bradley performed 
cell culture with reagents prepared by Yanyan Wang, ELISA, analyzed all data and drafted 
SCCM 2020 abstract. Huiping Zhou and Wanchun Tang reviewed data and abstract drafts. 
Mouse RAW 264.7 macrophage cells (ATCC, Rockville MD, USA) were plated into 60mm 
dishes with a density of 10*105 cells/dish and incubated with DMEM containing 10%FBS, 
1%PS overnight. Cell media was then changed to DMEM containing 1% FBS, 1%PS, and 
incubated for 4hrs (140, 141). They were then pretreated with WIN55 (5 μM) (142) for 2 hrs, 
then treated with LPS (12.5 ng/mL) for 6hrs and 24 hrs. At the end of treatment, culture media 
was collected and centrifuged at 14,000 x rpm for 1 min (143). Media protein levels of TNFα, 
IL6, and IL1β were quantified using commercial enzyme-linked immunosorbent assays 
(ELISAs) (R&D Systems, Minneapolis, MN, USA) (144). Concentrations were expressed as 
pg/mL. 
V. In vivo-WIN55 
Yan Xiao, Jadd Khoraki and Jennifer Bradley performed surgical technique. Jennifer Bradley 
performed ELISA and analyzed all dissertation data and Wanchun Tang reviewed. This study 
was approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth 
University. Animal care and handling were in accordance with the Guide for the Care and Use of 
Laboratory Animals and the ARRIVE guidelines. 
Animal Preparation 
Male Sprague Dawley rats, weighing between 450g and 550g were anesthetized by 
intraperitoneal injection of pentobarbital (45 mg/kg). The trachea was orally intubated with a 14-





was continuously monitored with a side-stream infrared CO2 analyzer (Capstar-100 Carbon 
Dioxide Analyzer; CWE, Ardmore, PA). A conventional lead II ECG was monitored 
continuously. A PE-50 catheter (Becton Dickinson, Franklin Lakes, NJ, USA) inserted into the 
descending aorta measured arterial pressure and was utilized for blood withdrawal. A 
thermocouple microprobe (9030-12-D-30, Columbus instruments, Columbus, OH, USA) inserted 
into the left femoral vein measured blood temperature. Another PE-50 catheter advanced into the 
right atrium measured right atrial pressure. A 3F catheter (Model C-PMS-301J; Cook Critical 
Care, Bloomington, IN) advanced into the right atrium was utilized to advance a pre-curved 
guidewire into the right ventricle to induce VF. Another PE-50 catheter inserted into the right 
femoral vein was utilized for drug infusion (Figure 17). All catheters were flushed intermittently 
with saline containing 2.5 IU/mL of crystalline bovine heparin (145). Aortic blood temperature 
was maintained at 37°C ± 0.5°C by a heated surgical board. ECG, aortic and right atrial 
pressures, ETCO2, and blood temperature were continuously recorded on a personal computer–












Figure 18. In vivo-WIN55 Experimental Protocol 
Experimental Procedures 
Animals were randomized into 2 groups (Figure 18) : 1) 2% Tween 80 (VF 6 min + CPR 8 
min, defibrillation and ROSC followed by infusion) (n=3), 2) SR141716A+WIN55 (IM 
Administration of SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide) 
before VF 6 min + CPR 8 min, defibrillation and ROSC followed by infusion) (n=6). At 5 
minutes after ROSC, either WIN55 (1 mg/kg/h) or vehicle (2% Tween-80 in 0.9% NaCl 
solution) was administered by continuous intravenous infusion with a syringe pump (Genie 
Touch; Kent Scientific Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114). Mechanical 
ventilation was established at a tidal volume of 0.60 mL/100g of body weight, a frequency of 
100 breaths/min, and FiO2 of 1.0. VF was then induced with a progressive increase in 60-Hz 
current to a maximum of 3.5 mA delivered to the right ventricular endocardium. Current flow 





precordial chest compressions, together with mechanical ventilation, were initiated using a 
pneumatically driven mechanical chest compressor. Precordial chest compressions were 
maintained at a rate of 200/min and synchronized to provide a compression/ ventilation ratio of 
2:1 with equal compression-relaxation for 8 min. Defibrillation was attempted with up to three 4-
J counter shocks. ROSC was defined as the return of supraventricular rhythm with a MAP above 
50 mm Hg for 5 min. 
 
Figure 19. SR141716A is an antagonist for CB1 (111) 
Measurements 
Hemodynamics and myocardial function 
Electrocardiogram, aortic and right atrial pressures, blood temperature, and ETCO2 values 
were continuously recorded on a personal computer-based data-acquisition system supported by 
WINDAQ software (DATAQ, Akron, OH). At baseline, 2 and 4 hours after ROSC, EF, CO, and 





Medical Systems, Eindhoven, Netherlands) with a 12.5 Hz transducer. EF and CO are adopted to 
estimate the myocardial contractility; MPI is adopted to estimate left ventricular diastolic 
function. The MPI, which combines time intervals related to systolic and diastolic functions 
reflecting the global cardiac function, is also calculated using the formula (a − b)/b, where 
a = mitral closure-to-opening interval (time interval from cessation to onset of mitral inflow) and 
b = ET (aortic flow ejection time, obtained at the left ventricle outflow tract) (145). 
ELISA Analysis 
One ml blood samples were collected at baseline, 2 and 4 hours after ROSC. After 
centrifugation (2,100×g, 10 min, 4°C) (146), plasma was removed and stored at −80°C for 
further ELISA analysis. Protein levels of TNFα, IL6, IL10 (R&D Systems, Minneapolis, MN, 
USA) S100A8 and cardiac troponin I (TNNI3) (LifeSpan BioSciences, Seattle, WA, USA) were 
quantified using commercial ELISA kits. ELISA measurement was performed following 
manufacturer’s instructions.  
VI. Statistical Analysis 
GraphPad PRISM version 9.0 for Windows (GraphPad Software Inc., San Diego, CA) was 
used to conduct analyses. Data are expressed as mean ± standard deviation (SD). Differences 
between greater than three groups were compared using a one-way analysis of variance 
(ANOVA) (Tukey or Bonferonni test for multiple comparisons). When only two groups were 
present, an unpaired student’s t-test was conducted. A p-value of <0.05 was considered 





CHAPTER 3: Cerebral and myocardial mitochondrial injury differ in a rat model of 
cardiac arrest and cardiopulmonary resuscitation 
 
RATIONALE 
Mitochondria are both targets and sources of damage during ischemia and reperfusion 
(22, 147). Following ischemia and reperfusion, mitochondrial dysfunction involves the increased 
production of reactive oxygen species (ROS), alteration of electron transfer activity, opening of 
the mitochondrial permeability transition pore (MPTP) and cytochrome c release (148-155). 
Ischemia damages the electron transport chain (ETC) (156) and decreases the rate of oxidative 
phosphorylation (OXPHOS) (157, 158). However, little is known regarding the effects of VF and 
CPR consistent with salvage by resuscitation on brain and heart mitochondrial function.  
We hypothesize that mitochondrial damage differs between the brain and heart. Brain 
mitochondria are more vulnerable to ischemia and suffer reperfusion injury in addition to 
ischemic alterations, resulting in diminished overall mitochondrial respiration following 
resuscitation (159). The purpose of this study was to measure mitochondrial function following 
cardiac arrest (CA) with and without cardiopulmonary resuscitation (CPR) using OXPHOS, ETC 
enzyme activity and calcium retention capacity (CRC) as an index of susceptibility to MPTP 
opening. 
RESULTS 
Body weight, blood temperature, ETCO2 and CPP during CPR were not different between 
VF+CPR and ROSC 1hr (Table 2). The maximal rate of OXPHOS was measured stimulated by 
2 mM ADP with glutamate as a complex I substrate. Oxidative phosphorylation was decreased 
by CA in brain and remained depressed through CPR and ROSC (Figure 20). Cardiac 





ROSC in SSM (Figure 21) and preserved function throughout in IFM (Figure 22). As previously 
described, SSM were more susceptible to injury than IFM (127, 150, 160). Inhibition of complex 
I activity is one of the earliest alterations in mitochondrial function due to ischemia (161). 
Maximal rate of OXPHOS stimulated by 2 mM ADP with TMPD-ascorbate as a complex IV 
substrate was no different in brain compared to heart mitochondria (Table 3).  
Table 2. Physiologic parameters  
 
           Variables                             VF+CPR              ROSC 1hr            
 
         Body Weight (g)                  487.8±19.2            487.2±6.4 
         Blood temperature (οC)         36.7±0.4                36.7±0.3 
         ETCO2 (mmHg)                    25.5±3.1                25.9±4.9     
         CPP (mmHg)                            27±3                   27.5±2.9 
 



















































Figure 20. BM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen 
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. 
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous 
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. 
Oxidative phosphorylation with glutamate as a complex I substrate was decreased by cardiac 
arrest in brain, and remained depressed through cardiopulmonary resuscitation. Mean ± SD, 
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. 


















































Figure 21. SSM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen 
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. 
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous 
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. 
Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS until the 
reperfusion of ROSC in SSM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 
**p<0.01 ***p<0.001 vs Sham N=6 in each group. My contribution (a) design of the 
















































Figure 22. IFM oxidative phosphorylation with glutamate as a complex I substrate- Oxygen 
consumption in mitochondria was measured using a Clark-type oxygen electrode at 30°C. 
Mitochondria were incubated in a solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 
5 mM KH2PO4, and 1 mg/ml bovine serum albumin, at pH 7.4. After depletion of endogenous 
substrates by addition of ADP, glutamate (complex I substrate) was added as an electron donor. 
Oxidative phosphorylation with glutamate as a complex I substrate preserved OXPHOS 
throughout in IFM. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 
***p<0.001 vs Sham N=6 in each group.  My contribution (a) design of the experiments (c) 









Table 3. Mean Percent Change of Rate of oxidative phosphorylation in brain and heart 
mitochondria using TMPD as complex IV substrate. 
 
            2mM ADP            BM                               SSM                      IFM 
                             
            VF                      Down 38±37.3          Down 28±14.3        Down 23±15.8      
            VF+CPR            Down 21±9.4            Down 17±10.2             Up 33±17.3     
            ROSC 1hr          Down 24±12             Down 33±29.7        Down 39±23.7     
 
Mean ± SD, p>0.05 vs Sham rates: BM 2672±666.8; SSM 5844±1539.6; IFM 3968±1257.6 
nAO/min/mg mitochondrial protein; N=6 in each group. Oxygen consumption in mitochondria 
was measured using a Clark-type oxygen electrode at 30°C. Mitochondria were incubated in a 
solution containing 80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, and 1 mg/ml 
bovine serum albumin, at pH 7.4. After depletion of endogenous substrates by addition of ADP, 
TMPD-ascorbate (complex IV substrate) was added as an electron donor. 
 
Enzyme activity of ETC complexes was measured to identify the primary sites most 
affected by ischemia within the ETC. CA resulted in sustained damage to complex I in brain 
mitochondria (Figure 23). NADH:ferricyanide oxidoreductase activity decreased following 
ROSC, suggesting that reperfusion caused damage to the NADH oxidase portion of the complex 
(Figure 24). In contrast, complexes II and III remained unaltered (Table 4). In this rat model of 
CA and CPR, brain complex I is more vulnerable to damage during ischemia and reperfusion 
than complex II or complex III. Complex I in brain is also more susceptible to damage than 












































Figure 23. BM enzyme activity confirmation of Complex I damage. CA resulted in sustained 
damage to complex I in brain mitochondria. Mean ± SD, One-way ANOVA, Tukey Post-hoc 
*p<0.05 **p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the 









































Figure 24. BM enzyme activity of NADH:ferricyanide oxidoreductase-decreased following 
return of spontaneous circulation. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 
**p<0.01 ***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the 










Table 4. Brain and heart mitochondria Electron Transport Chain Results. 
 
           Complex II                    BM                   SSM                          IFM 
 
            SHAM                     274.8±69.3          101.4±47.9              119.6±28.2     
            VF                            230.2±67.9            --                            --       
            VF+CPR                     223±39.6               70±10.4                 150±26   
            ROSC 1hr        178±70.1            89.6±14                 128.4±36.6     
 
           Complex III                   BM                   SSM                          IFM 
 
            SHAM                      3572±739.4        4128.2±1251.7          4974±554.3      
            VF                         2896.4±672.5         --                              --       
            VF+CPR                3039.8±365.8        1869.2±515*             4722±1065.7   
            ROSC 1hr                 3043±698.3        2501.6±1543.9       4045.6±581.5     
 
Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham. Enzyme 
activity is mU/mg mitochondrial protein. N=5 in each group. 
 
 In the heart, VF+CPR decreased complex I activity in SSM and remained low during the 
first hour of ROSC (Figure 25). NADH:ferricyanide oxidoreductase activity was decreased 
concomitant with the decrease in complex I activity, suggesting that the site of damage is in the 
NADH oxidase portion of the complex (Figure 26). In contrast, IFM were relatively free of 
damage with a non-significant trend of decreased complex I activity (Figure 27). Complexes II 




















































Figure 25. SSM enzyme activity confirmation of Complex I damage. VF+CPR decreased 
complex I activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 
***p<0.001 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) 









































Figure 26. SSM enzyme activity of NADH:ferricyanide oxidoreductase-decreased NFR 
activity. Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs 













































Figure 27. IFM enzyme activity of Complex I. Mean ± SD, One-way ANOVA, Tukey Post-
hoc p>0.05 vs Sham N=5 in each group. My contribution (a) design of the experiments (c) 
Analysis of the data. 
Calcium retention capacity (CRC) in brain decreased rapidly and was abnormal 
throughout CA and CPR (Figure 28), in contrast to heart CRC that only decreased following 
ROSC in both SSM and IFM (Figure 29 and Figure 30). Thus, brain mitochondria are more 
susceptible to MPTP opening compared to heart mitochondria. Furthermore, an increased 
susceptibility to MPTP opening is already evident in brain mitochondria during the initial period 









































Figure 28. BM calcium retention capacity (CRC)-measured as an index of susceptibility to 
MPTP opening. CRC in brain rapidly decreased, and was abnormal throughout CA and CPR. 
Mean ± SD, One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in 








































Figure 29. SSM calcium retention capacity (CRC)-measured as an index of susceptibility to 
MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way 
ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My 







































Figure 30. IFM calcium retention capacity (CRC)-measured as an index of susceptibility to 
MPTP opening. Heart mitochondria only decreased following ROSC. Mean ± SD, One-way 
ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs Sham N=6 in each group. My 
contribution (a) design of the experiments (c) Analysis of the data. 
DISCUSSION 
Our experimental CA/CPR (145, 162, 163) model indicates that mitochondrial damage is 
different between rat brain and heart. Brain mitochondria are more sensitive to global ischemia. 
Heart SSM are minimally damaged whereas IFM remain intact. In contrast, mitochondrial 
OXPHOS and ETC indicate that complex I is markedly decreased in brain. This is in line with 
Borutaite et al. reporting a decrease in complex I activity after 20-25min of global no-flow 
ischemia (161). Alleviation of complex I injury may be an important therapeutic target to reduce 





neuroprotection after CA (9). Donnino et al’s characterization of mitochondrial injury after 
cardiac arrest (COMICA) clinical trial demonstrated mixed results with mitochondrial injury 
markers post-arrest. Pathways in humans remain incompletely characterized and need to be 
studied further (34). 
OXPHOS, with glutamate is used to assess the response of intact mitochondria to 
ischemia (164). Ischemia leads to progressive injury to the ETC (22, 127) and ischemic 
mitochondrial damage occurs more rapidly in SSM, which are located beneath the plasma 
membrane, than in IFM, which are located between the myofibrils (127). SSM were more 
susceptible to injury than IFM, which is consistent with previous studies (127, 150, 160).  SSM 
and IFM injury induced by 8 min of CA did not progress despite markedly reduced blood flow 
and oxygen supply during 8 min of CPR. Results are less severe than studies of more prolonged 
ischemia (15, 131, 150). Myocardial mitochondria show a markedly increased susceptibility to 
opening of the MPTP following a more robust reperfusion resulting from one hour of ROSC. 
There is a significant decrease in mitochondrial function following 25 min of stop-flow 
myocardial ischemia (129). CPR is sufficient to interrupt or slow the ongoing ischemic insult 
imposed on myocardial mitochondria, and possibly extends the period of mitochondrial viability 
during early stages of CA. 
The rate of OXPHOS was markedly decreased in brain mitochondria oxidizing complex I 
substrate (Figure 20). A complex I defect occurs during cerebral ischemia or CA. This was 
confirmed by enzyme activity measurement (Figure 23). Furthermore, the activity of 
NADH:ferricyanide oxidoreductase (NFR) was decreased (127) (Figure 24).  Ferricyanide is an 
artificial electron acceptor that is reduced by the flavin mononucleotide cofactor in the NADH 





cardiac mitochondria due to a decrease in the NADH dehydrogenase component likely due to 
loss of the flavin mononucleotide coenzyme (156, 166-168). Damage to the NADH 
dehydrogenase component of complex I can increase electron leak and ROS production, 
contributing to brain damage after CA (168). Reperfusion of ischemic brain also leads to massive 
generation of ROS (169). Activated microglia convert into a pro‑inflammatory (M1) phenotype 
that obtains macrophage-like properties (such as antigen presentation) and generates several 
pro‑inflammatory mediators (such as IL1 β, TNFα, and ROS) that can disrupt the blood brain 
barrier (BBB) (9). Generation of ROS, including from complex I itself, can lead to complex I 
damage (125, 129, 169). Development of ischemic acidosis during CA might also facilitate 
flavoprotein dissociation, hindering electron transfer and impairing complex I activity (15). 
Consistent with the decrease in NFR, ischemia induced loss of FMN may contribute (170). 
Ischemia also damages complex I at sites more distal in the path of electron flow at iron sulfur 
centers, including immediately proximal to the quinol binding site (129, 171). Complex I also 
undergoes a conformational change from an active form to a “de-active” form (170). However, 
the de-active form of complex I should be reactivated under conditions of the ETC assay. 
Whether these potential contributing factors contribute to the beneficial effects of CPR remains 
to be explored. In general, brain mitochondrial dysfunction following ischemia is associated with 
impaired complex I activity.  
Mitochondrial dysfunction after resuscitation from CA due to impaired electron transport 
through the respiratory complexes of the ETC leading to decreased rates of OXPHOS is poorly 
characterized in patients who achieve ROSC. ETC dysfunction reduces mitochondrial membrane 
potential. Impaired OXPHOS leads to decreased generation of high energy phosphates. Direct 





favoring oxidative tissue injury. Damage to the mitochondrial inner membrane leads to 
decreased membrane potential and favors cytochrome c release into the cytosol, which activates 
cell death (14). Mitochondrial defects are associated with reduced ATP generation, metabolic 
failure, altered signaling pathways, and induction of apoptosis.  
Susceptibility of MPTP opening has been implicated as a key mechanism underlying both 
necrotic and apoptotic cell death during ischemia and reperfusion (172-174). Kristian et al. report 
mitochondria energized with either electron transport complex I or complex II substrates within 
an acidic environment promote permeability transition pore opening (175). MPTP opening 
increases the permeability of both inner and outer mitochondrial membranes. Because of MPTP 
opening, solutes with a molecular mass of up to 1,500 Da non-selectively diffuse across the 
mitochondrial inner membrane, leading to mitochondrial depolarization, uncoupling of 
OXPHOS, and large amplitude swelling, leading to ATP depletion and cell death (174). The 
effectiveness of mPTP inhibitors to protect the myocardium has not been observed in clinical 
trials of acute myocardial infarction (176). However, neuronal cyclophilin D represents a 
promising therapeutic target for Alzheimer’s disease (177). The development of nopeptidic small 
molecule inhibitors of cyclophilin D could be a promising approach for cardiac arrest as our 
study demonstrates a markedly increased susceptibility to MPTP opening within brain 
mitochondria. This occurs during the initial period of ischemia due to CA and persists 
throughout the course of CPR, including resuscitation and ROSC. In contrast, the susceptibility 
of cardiac MPTP opening increases during ROSC. Therefore, brain MPTP susceptibility during 
ischemia is different than in heart (178). Briston et al. reports complex I-driven respiration is 
reduced after MPTP opening (179). Cardiac mitochondria are more resistant to damage during 





result of calcium overload associated with reperfusion (180, 181). Therefore, reperfusion injury 
affects heart mitochondria even after short durations of ischemia.  
A complex I targeted therapeutic could also potentially ameliorate brain mitochondrial 
dysfunction after cardiac arrest.  Preservation of complex I activity could potentially provide 
better clinical outcomes of survival with good neurological function (currently only 8.2%) and 
survival to hospital discharge (currently 10.4%) (1). Further research is necessary regarding 
mechanism among cardiac arrest victims. In a middle cerebral artery occlusion (MCAO) rat 
model, decreased activity of Complex I, III, and IV after ischemia/reperfusion injury contributed 
to decreased mitochondrial function, which was restored with a low-dose of methylene blue 
(MB) (182). The neuroprotective role of MB in cerebral ischemia has been suggested to be 
caused by increased mitophagy and maintenance of mitochondrial membrane potential (182).  
Therapeutic Hypothermia is a standard intervention to improve outcomes following 
cardiac arrest and cardiopulmonary resuscitation. Although therapeutic hypothermia can preserve 
energy stores, current work also suggests that reactive oxygen species production is also 
decreased (183, 184). This is plausible, since hypothermia decreases rates of electron transport. 
Transient, partial blockade of electron transport during early reperfusion protects the heart (125, 
185, 186). Hypothermia slows electron transport and reactive oxygen species generation in the 
intact heart with a similar profile to that of blockade of electron transport (187). Thus, there is a 
premise for protection of the brain and heart following cardiac arrest by therapeutic hypothermia 
(WIN55 via CB1). 
Complex I preservation would mitigate lowered levels of ATP, dramatic shifts in calcium 
concentration and cell swelling.  Our study demonstrates the brain is most reliant on 





brain compared to the heart. Reperfusion of ischemic brain will lead to massive generation of 
free radicals such as ROS and activation of several signaling pathways (9). Our findings suggest 
that CPR is able to preserve heart mitochondrial function and viability longer than that of brain 
during ongoing global ischemia despite low blood flow and oxygen delivery. A metabolic phase 
of cardiac arrest (188) occurs earlier than reported previously. Therefore, preservation of brain 
complex I activity during CA will likely continue to emerge as a critical therapeutic target. 
WIN55 could be a pharmacologic tool as it has been shown to decrease brain injury reducing 
both delayed cell death and glial damage (38). 
CONCLUSIONS 
Brain mitochondria are more sensitive to global ischemia compared to heart 
mitochondria. Additionally, complex I is the most sensitive ETC complex to ischemic injury and 
its activity determines rate of OXPHOS following CA and resuscitation. Preservation of brain 
mitochondrial activity and function during CA may enhance outcomes and recovery. Future 
work is needed to improve current clinical resuscitation success rates by addressing an early 
therapeutic target preserving complex I activity during CA.  
LIMITATIONS 
Our generalized use of brain and heart within this dissertation are the cerebrum and 
whole heart, which is a limitation within the current study. Future studies are needed to address 
the following: visualization of structural damage using electron microscopy, measurement of 
reactive oxygen species production, measurement of pro-inflammatory mediators and the use of 
interventions to enhance complex I activity to determine beneficial effects. Analysis of 






CHAPTER 4: Quantitative mass spectrometric analysis of cardiac whole tissue lysate 
proteome changes from our rat cardiac arrest and cardiopulmonary resuscitation model 
 
RATIONALE 
For aerobic cells ischemia is a critical change in the oxygen demand to delivery ratio 
(189). CA is characterized by severe and generalized ischemia that persists during resuscitation 
efforts and reverses only after ROSC (2). Ischemia causes reperfusion injury. In general, 
reperfusion injury is proportional to the magnitude of the preceding period of ischemia. All 
tissues can withstand variably short periods of ischemia that do not produce detectable functional 
deficits or evidence of injury. However, once a critical duration of ischemia is exceeded, which 
varies by cell type and organ, cell injury and/or death ensues (190). Within the usual timeframe 
of CA and resuscitation, ischemic injury is most severe in organs with high metabolic demands, 
such as the brain and heart (2). 
 Studies have shown that S100A8/A9 levels positively correlate with risk of acute 
myocardial infarction (191, 192). Additionally, site-specific measurements of S100A8/A9 in 
patients with acute coronary syndrome demonstrate that S100A8/A9 is markedly more elevated 
at the site of coronary occlusion compared to systemic circulation (193). Further support of this 
finding, immunostaining, reveals S100A8/A9 is specifically expressed in neutrophils and 
macrophages infiltrating the myocardium post-infarction (192). Together, these studies 
demonstrate S100A8/A9 is a major player in local inflammation caused by acute cardiovascular 
events. 
We hypothesize that S100A8/A9 expression increases within heart whole tissue lysate 
after CA and CPR. The purpose of this study was to measure proteome changes following CA 







Quantification of total protein concentration of supernatant was determined by a BCA™ 
Protein Assay (Figure 31). 4,997 proteins (Sham 3) were quantitatively identified across 3 
groups of 11 samples using one TMT10plex Isobaric Label Reagent Set plus TMT11-131C 
Label Reagent. 239 of the 4,997 proteins identified to be differentially expressed (fold change 
>=1.25, p<0.05, n=3 or 4) upon CPR compared to Sham+Norm (Figure 32). 104 proteins 
changed by at least 25% highlighted in purple (fold change >=1.25, p<0.05). Housekeeping 
proteins are not changed. Another volcano plot of the 171 proteins changed <0.75 and >1.25 was 
compared between CPR and Sham+Norm (Figure 33).   
Four proteins that were most significant were Fibrinogen gamma chain precursor 
(functions in hemostasis as one primary component of blood clots and functions during the early 
stages of wound repair to guide cell migration during re-epithelialization) (194), Parvalbumin 
alpha (in muscle it is thought to be involved in relaxation after contraction) (195), G-protein 
coupled receptor (involved in cell recognition and communication processes) and Transketolase-
like protein 2 isoform X1(protein has several cofactor biding sites including calcium binding) 
(196). These four proteins with the greatest change in expression are noted, however, we focused 
on S100A8 and S100A9 due to Li et al. connecting S100A8/A9 signaling with mitochondrial 



























Figure 31. Supernatant BCA Assay. Mean ± SD, One-way ANOVA, Tukey Post-hoc p> 0.05 
vs Norm N=3 (Norm) or 4 (Sham and CPR). Equal protein loading allows for comparison of 




























Figure 32. Volcano Plot 4,997 Proteins Identified by Poochon Scientific. My contribution (a) 
design of the experiments (c) Re-analysis of the data provided by Poochon Scientific. 




























Figure 33. Volcano Plot CPR/Norm+Sham Ratio <0.75 and >1.25-171 Proteins Identified. 
Accession Numbers 61098186-Fibrinogen gamma chain precursor [Rattus norvegicus], 
11968064-Parvalbumin alpha [Rattus norvegicus], 60389876- G-protein coupled receptor and 
564388869- Transketolase-like protein 2 isoform X1 [Rattus norvegicus]. Pink are S100A8 and 
S100A9[Rattus norvegicus]. My contribution (a) design of the experiments (c) Re-analysis of the 
data provided by Poochon Scientific. 
  Kyoto Encyclopedia of Genes and Genomes (KEGG), a collection of genomes 
and biological pathways, was used to map pathways from the 4,997 proteins identified by 
Poochon Scientific (3,195 Kegg were able to be converted from the 4,997 NCBI). Biological 
pathways such as oxidative phosphorylation (Figure 34), complement and coagulation cascades 
(Figure 35), toll-like receptor signaling (Figure 36) and chemokine signaling were mapped 
(Figure 37). The complement and coagulation cascade was identified to have multiple proteins 
expressed after CA and CPR (64 Kegg were able to be converted from the 104 proteins >1.25) 







Figure 34. 3,195 converted Kegg proteins rno00190 Oxidative phosphorylation-Rattus 
norvegicus (rat) (81). Red indicates gene presence. My contribution (a) design of the 






Figure 35. 3,195 converted Kegg proteins rno04610 Complement and coagulation cascades- 
Rattus norvegicus (rat) (36). Red indicates gene presence. (a) design of the experiments (c) Kegg 








Figure 36. 3,195 converted Kegg proteins rno04620 Toll-like receptor signaling pathway- 
Rattus norvegicus (rat) (16). Red indicates gene presence. (a) design of the experiments (c) Kegg 









Figure 37. 3,195 converted Kegg proteins rno04062 Chemokine signaling pathway- Rattus 
norvegicus (rat) (37). Red indicates gene presence. (a) design of the experiments (c) Kegg 






Figure 38. 64 converted Kegg proteins (CPR/Sham+Norm Ratio -log10 p>1.25 ) rno04610 
Complement and coagulation cascades-Rattus norvegicus (rat) (13). Red indicates gene 
presence. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon 
Scientific. 
A scatter plot for the CA and CPR data that was used to create the KEGG pathway in 
Figure 38 was generated through multidimensional scaling. Similar GO terms are grouped closer 
together in the plot based on similar semantics (Figure 39). Color of biological processes clusters 
corresponds to the p-value input provided by Poochon Scientific. Biological processes that are 







Figure 39. REVIGO gene ontology clustering of biological processes based on semantic 
similarity. (a) design of the experiments (c) Kegg pathway analysis of data provided by Poochon 
Scientific. 
DISCUSSION 
CPR/Sham+Norm ratio DAVID 6.8 analysis showed S100A8/A9 expression increased 
(CPR avg higher than Sham+Norm avg). Intracellular S100A8/A9 is best known for the ability 
to regulate transendothelial migration of leukocytes (73, 197). Both are constitutively expressed 
in neutrophils, monocytes and dendritic cells. However, they can also be intensely upregulated 





Extracellular S100A8/A9 is a damage associated molecular pattern after being released from 
damaged or activated cells, therefore increased expression seen in heart tissue lysates obtained at 
ROSC is due to ischemia/reperfusion injury from CA.  
Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial 
IR procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart. Proteomic analysis 
from Poochon Scientific was performed on heart tissue lysate collected at ROSC (no more than 
30 minutes from VF). S100A8/A9 is critical for IR induced myocardial death, the sequelae of 
adverse cardiac remodeling, and heart failure (132). The release of S100A8 and S100A9 can 
induce C3/CFB complement activation and secretion of multiple cytokines in inflammatory cells 
to sustain and exacerbate inflammation (69). Therefore, they control early stages of inflammation 
for cardiac IR injury after CA. Inhibition of S100A8/A9 activity during CA could be a potential 
therapeutic target. 
CONCLUSIONS 
S100A8 and S100A9 have promising potential as new biomarkers for cardiovascular 
inflammation. Inhibition of S100A8/A9 activity during CA may enhance outcomes and recovery. 
LIMITATIONS 
Confirmation of proteomic analysis still needs to be done at the tissue level. If we have 
tissue available after lipidomic analysis from a collaborator-a future study could include 
immunoblot of the brain and heart for S100A8 and S100A9. Du et al. discovered global ischemia 
did not alter immunoblot protein levels of S100A8 and S100A9 at 0, 30 and 60 min. In vivo 
ischemia for 2hrs resulted in strong S100A8 and S100A9 overexpression (198). Li et al reported 
serum S100A8/A9 levels were significantly increased 1 day after percutaneous coronary 





look at expression of S100A8 and S100A9 peptides in brain and heart and protein levels in 
plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of S100A8/A9 
protein expression with a treatment group of WIN55 would further enhance the mechanism of 






CHAPTER 5: Anti-Inflammatory activity of WIN55, 212-2, a non-selective cannabinoid 
CB1/CB2 receptor agonist in cultured RAW264.7 macrophage cells 
 
RATIONALE 
Macrophages are innate immune cells that form the first line of defense against invading 
pathogens (62). Under different pathophysiologic conditions, activated macrophages are capable 
of differentiating into phenotypically different states, including the classically activated (M1) and 
the alternatively activated (M2) (61). M1 macrophages are characterized by the production of 
pro-inflammatory cytokines, such as IL1, IL6, IL12, TNFα and chemokines, involved in various 
inflammatory processes (61). They are major producers of TNFα and are also highly responsive 
to TNFα (62). TNFα is rapidly released after trauma, infection, or exposure to bacterial-derived 
LPS and has been shown to be one of the most abundant early mediators in inflamed tissue (62). 
TLR signals have an important role in regulating macrophage polarization. In particular, 
the TLR4 ligand LPS promotes macrophage differentiation toward M1 phenotype (61). TNFα 
has been shown to play a pivotal role in orchestrating the cytokine cascade in many 
inflammatory diseases and because of this role as a “master-regulator” of inflammatory cytokine 
production, it has been proposed as a therapeutic target for a number of diseases (62). IL6 is also 
another pro-inflammatory cytokine secreted by monocytes and macrophages after engagement of 
Toll-like receptors (TLRs) that promotes inflammatory events (66, 199).  
Hao et al. reported oxLDL-induced TNFα expression and ROS generation in RAW 264.7 
mouse macrophages is considerably reduced by the synthetic cannabinoid WIN55. Reduced 
TNFα expression and ROS production is mainly via the CB2 receptor, and partially linked with 
the CB1 receptor. MAPK and NF-kappa β are inhibited by WIN55 activated CB1/CB2 receptor 
signaling, suggesting their involvement in the attenuation of TNFα expression and ROS 





inflammatory effects against LPS induced pro-inflammatory mediators TNFα, IL6 and IL1β. The 
purpose of this study was to measure LPS induced TNFα, IL6 and IL1β protein expression with 
and without pre-treatment of WIN55 in mouse RAW 264.7 macrophages. 
RESULTS 
 TNFα, IL6 and IL1β were all increased following LPS stimulation. Pre-treatment with 
WIN55 decreased TNF-α (9,206±847 (SD) pg/mL) compared to 6hrs LPS (15,694±2,285 
p<0.05) (Figure 40). Pre-treatment with WIN55 also decreased IL6 (7,136±1,238) and IL-1β 
(89±21) compared to 24hrs LPS (10,318±2,092 and 207±26 p<0.05) (Figure 41 






























Figure 40. Pre-treatment with WIN55 decreased TNFα compared to 6hrs LPS Mean ± SD, 
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=3 in each group. 
My contribution (a) design of the experiments (b) execution of experimental procedure (c) 




























Figure 41. Pre-treatment with WIN55 decreased IL6 compared to 24hrs LPS Mean ± SD, 
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=6 in each group. 
My contribution (a) design of the experiments (b) execution of experimental procedure (c) 






























Figure 42. Pre-treatment with WIN55 decreased IL1β compared to 24hrs LPS Mean ± SD, 
One-way ANOVA, Tukey Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs LPS N=6 in each group. 
My contribution (a) design of the experiments (b) execution of experimental procedure (c) 








LPS is a ligand for TLR 4. It is an endotoxin from the walls of Gram-negative bacteria 
and is a potent stimulator of inflammatory cytokines in macrophages (201). The initial acute 
innate immune response to LPS primes the adaptive immune system against further infection 
(202). Macrophages are the major players in both innate and adaptive inflammatory responses.  
For this reason, WIN55 was examined for its effect on the expression of TNFα, IL6 and IL1β 
protein in mouse RAW 264.7 macrophage cells stimulated with LPS.   Our macrophage cell 
culture model indicates that WIN55 inhibited LPS stimulated proinflammatory mediators. 
CONCLUSION 
WIN55 inhibited LPS induced expression of pro-inflammatory cytokines. 
LIMITATIONS 
Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vitro. 
There are two different antagonists of CB2 (SR144528 (114) and AM630 (200)) that can be 
tested to determine if administration blocks the effect of WIN55. Antagonists of CB1 such as 
SR141716A and AM251 also need to be tested to determine if administration blocks the effect of 
WIN55. Further studies are also needed using more specific CB2 receptor agonists such as 
HU308 or JWH-133 (200). Treatment with recombinant S100A8 proteins should also be 
determined. RAW264.7 macrophage cells should be treated with WIN55 (5 μM) (142) for 2 h, 
then treated with S100A8 for 6hrs and 24 hrs. S100A8 acts not only as a chemoattractant to 
macrophages but also as a proinflammatory factor (203). Inhibitors of S100A8 and/or S100A9 
should also be tested in vitro. PPARγ expression should also be determined as WIN55 induced 
PPARγ expression was partially attenuated by AM630 in BEL-7402 cells (204). The effects of 





(204). PPAR-γ agonists significantly reduced adipose S100A8 mRNA level and plasma 
S100A8/A9 complex concentrations in obese diabetic mice and human subjects (203). After 
these effects are determined in RAW264.7 macrophage cells confirmation studies can be 







CHAPTER 6: One mechanism of anti-inflammatory activity of cannabinoid agonist 
WIN55, 212-2 on outcomes of CPR is binding cannabinoid receptor 2 (CB2)  
 
RATIONALE 
In non-traumatic CA, common causes are ventricular fibrillation cardiac arrest (VFCA) 
and asphyxial cardiac arrest (ACA) (205). Recent data from several large population cohorts, 
covering over 40,000 patients, demonstrate proportions of initial ventricular 
tachycardia/ventricular fibrillation in the range of 20-25% (13). The 2016 weighted national 
estimate of emergency department visits with a principal diagnosis of either CA or ventricular 
fibrillation/flutter was 183,629 patients among the National Emergency Department Sample (1). 
For this reason, our physiologically relevant VF model developed in 1988 has been used in 
approximately 70 peer-reviewed publications examining resuscitation aspects including: its 
physiology and pathophysiology, determinants of resuscitability, pharmacologic interventions, 
and effects of cell therapies (206). Once we confirmed in vitro WIN55 inhibited LPS induced 
expression of pro-inflammatory cytokines within mouse RAW 264.7 macrophage cells we then 
explored our experimental in vivo CA/CPR (145, 162, 163) rat model. 
The Weil Institute has published that infusion of WIN55 decreases body temperature 
from 37 to 34oC within 4 hours after infusion (114, 207). All animals that received WIN55 
survive for more than 72 hours with minimal neurological deficits. Post-resuscitation myocardial 
function is significantly better than control. We therefore demonstrate the feasibility that 
therapeutic hypothermia could be induced pharmacologically in settings of CPR without 
compromising outcomes (207). We further demonstrate that hypothermia effects of WIN55 are 





The role of endocannabinoids (eCBs) in the cardiovascular system is paradoxical because 
both positive and negative effects are observed, particularly in conditions of cardiovascular 
dysfunction (209). We hypothesize that CA will increase plasma concentrations of TNFα, IL6 
and IL10. Therefore, plasma cytokine levels will be elevated after resuscitation. Intramuscular 
(IM) administration of SR141716A before VF+CPR followed by infusion of WIN55 5 min after 
ROSC will prohibit the release of inflammatory mediators caused by CA via the CB2 receptor. 
The purpose of this study was to measure hemodynamics (electrocardiogram, aortic and right 
atrial pressures, blood temperature, and ETCO2 values), myocardial function (EF, CO, and MPI) 
and plasma protein concentrations following CA with and without administration of SR141716A 
before VF+CPR followed by infusion of WIN55 5 min after ROSC. 
RESULTS 
 Our most recent WIN55 publication and our current studies administered WIN55 5 
minutes after ROSC. Blood temperature in WIN55 + Hypothermia decreased progressively from 
36.8°C ± 0.2°C to 35.1°C ± 0.5°C during the first hour of infusion and reached 33.3°C ± 0.3°C at 
4 hours after infusion (145). Duration of reduced blood temperatures did not have a significant 
difference between WIN55 + Hypothermia and Hypothermia, which had a similar rate for 
temperature drop. Due to the use of a heated surgical board, there was no significant reduction in 
blood temperature in animals with WIN55 + Normothermia which was similar to Normothermia. 
There was no significant reduction in blood temperature in animals pretreated with SR141716A 



























































Figure 43. Blood temperature was not different between groups. Mean ± SD, Unpaired t test, 
p>0.05 vs 2% Tween N=3, SR141716A+WIN55 N=6.  My contribution (a) design of the 
experiments (b) execution of experimental procedure (c) Analysis of the data. 
MAP and HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased 
significantly compared with Normothermia at ROSC 1hr, 2hrs, 3hrs, and 4hrs (Figure 44 and 
Figure 45), while ETCO2 in WIN55 + Hypothermia increased significantly compared with 
Normothermia (Figure 46) (145). HR in SR141716A+WIN55 decreased significantly compared 
to 2% Tween 80 at ROSC 2hrs and 3hrs (Figure 47) while ETCO2 increased significantly 
compared with 2% Tween 80 at ROSC 1hr and 4hrs (Figure 48). Administration of 



































































Figure 44. MAP in WIN55 + Hypothermia and WIN55 + Normothermia decreased 
significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-
hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) 




































































Figure 45. HR in WIN55 + Hypothermia and WIN55 + Normothermia decreased 
significantly compared with Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-
hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in each group. My contribution (a) 


























































Figure 46. ETCO2 in WIN55 + Hypothermia increased significantly compared with 
Normothermia. Mean ± SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 
***p<0.001 vs normothermia N=6 in each group. My contribution (a) design of the experiments 



























































Figure 47. HR in SR141716A+WIN55 decreased significantly compared to 2% Tween 80 at 
ROSC 2hrs and 3hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% 
Tween N=3, SR141716A+WIN55 N=6.  My contribution (a) design of the experiments (b) 



























































Figure 48. ETCO2 increased significantly compared with 2% Tween 80 at ROSC 1hr and 
4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, 
SR141716A+WIN55 N=6.  My contribution (a) design of the experiments (b) execution of 
experimental procedure (c) Analysis of the data. 
There was a significant improvement in myocardial function as measured by CO, EF, and 
MPI, in animals treated with WIN55 + Hypothermia beginning at 1 hour after start of infusion. 
WIN55 + Hypothermia significantly improved at ROSC 4hrs compared with Physical 
Hypothermia (Figure 49, Figure 50 and Figure 51) (145). MPI in SR141716A+WIN55 



























Figure 49. Significant improvement in myocardial function as measured by CO. Mean ± 
SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia 
N=6 in each group. My contribution (a) design of the experiments (c) Re-analysis of the data. 




















Figure 50. Significant improvement in myocardial function as measured by EF. Mean ± SD, 
One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia N=6 in 






















Figure 51. Significant improvement in myocardial function as measured by MPI. Mean ± 
SD, One-way ANOVA, Bonferroni Post-hoc *p<0.05 **p<0.01 ***p<0.001 vs normothermia 





































Figure 52. MPI in SR141716A+WIN55 increased significantly compared with 2% Tween 
80 at ROSC 4hrs.  Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween 
N=3, SR141716A+WIN55 N=6.  My contribution (a) design of the experiments (b) execution of 
experimental procedure (c) Analysis of the data. 
 TNFα, IL6, cardiac troponin I and IL10 expression in plasma were all increased 
following CA/CPR (Figure 53, Figure 54, Figure 55 and Figure 56). IM Administration of 
SR141716A (Figure 19) (5 mg/kg, dissolved in 0.1 mL dimethylsulfoxide) before VF 6 min + 
CPR 8 min, defibrillation and ROSC followed by infusion) of WIN55 (1 mg/kg/h) administered 
by continuous intravenous infusion with a syringe pump (Genie Touch; Kent Scientific 
Corporation) for 4 hours at a rate of 1.4 mL/kg/h (114) decreased expression in plasma TNFα, 
IL6, and IL10 at ROSC 4hrs (Figure 53, Figure 54 and Figure 56). Cardiac troponin I and 








































Figure 53. Plasma TNFα. IM Administration of SR141716A before VF+CPR followed by 
infusion of WIN55 5 min after ROSC significantly decreased TNFα plasma protein expression at 
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, 
SR141716A+WIN55 N=5.  My contribution (a) design of the experiments (b) execution of 



































Figure 54. Plasma IL6. IM Administration of SR141716A before VF+CPR followed by 
infusion of WIN55 5 min after ROSC significantly decreased IL6 plasma protein expression at 
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs 2% Tween N=3, 
SR141716A+WIN55 N=3.  My contribution (a) design of the experiments (b) execution of 




































Figure 55. Plasma Troponin I. IM Administration of SR141716A before VF+CPR followed by 
infusion of WIN55 5 min after ROSC had no effect on cardiac troponin I plasma protein 
expression at ROSC 4hrs. Mean ± SD, Unpaired t test, p>0.05 vs %Tween N=3, 
SR141716A+WIN55 N=5.  My contribution (a) design of the experiments (b) execution of 


































Figure 56. Plasma IL10. IM Administration of SR141716A before VF+CPR followed by 
infusion of WIN55 5 min after ROSC decreased IL10 plasma protein expression at ROSC 4hrs. 
Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs %Tween N=3, 
SR141716A+WIN55 N=5.  My contribution (a) design of the experiments (b) execution of 






































Figure 57. Plasma S100A8.  IM Administration of SR141716A before VF+CPR followed by 
infusion of WIN55 5 min after ROSC had no effect on S100A8 plasma protein expression at 
ROSC 4hrs. Mean ± SD, Unpaired t test, *p<0.05 **p<0.01 ***p<0.001 vs %Tween N=3, 
SR141716A+WIN55 N=5.  My contribution (a) design of the experiments (b) execution of 
experimental procedure (c) Analysis of the data. 
DISCUSSION 
 In the cardiovascular system, CB2 is present in various cell types (97). Therefore, IM 
Administration of SR141716A (CB1 antagonist) before VF+CPR followed by infusion of WIN55 
(CB1 and CB2 agonist) 5 min after ROSC was used as a treatment group to determine CB2 
agonist response to CA/CPR. HR decreased significantly at ROSC 2hrs and 3hrs while ETCO2 
increased significantly at ROSC 1hr through 4hrs with treatment. MPI also increased 
significantly at ROSC 4hrs. Our experimental CA/CPR (145, 162, 163) model indicates that 
TNFα, IL6, and IL10 plasma protein expression is decreased at ROSC 4hrs with 
SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression did not 





Relative cardiac S100A8 and S100A9 mRNA expression in mice subjected to myocardial IR 
procedures had peak S100A8/A9 mRNA expression at 6hrs in the heart (132). 
CONCLUSION 
TNFα, IL6, and IL10 plasma protein expression decreased at ROSC 4hrs with 
SR141716A+WIN55 treatment. Cardiac troponin I and S100A8 protein expression does not 
change. 
LIMITATIONS 
Confirmation of the CB2 receptor as anti-inflammatory still needs to be validated in vivo. 
There are two different antagonists of CB2 (SR144528(114) and AM630(200)) that can be tested 
to determine if administration blocks the anti-inflammatory effect of WIN55. Antagonists of CB1 
such as AM251 also need to be tested to determine if administration blocks the anti-
inflammatory effect of WIN55. Further studies are also needed using more specific CB2 receptor 
agonists such as HU308 or JWH-133(200).  
If we have tissue available after lipidomic analysis from a collaborator-a future study 
could include immunoblot of the brain and heart for S100A8 and S100A9. Therefore, future 
studies could look at expression of S100A8 and S100A9 peptides in brain and heart and protein 
levels in plasma at ROSC 4hrs or with a survival model at 24, 48 and 72hrs. Analysis of 
S100A8/A9 protein expression with a treatment group of WIN55 would further enhance the 
mechanism of this pharmacologic tool. Inhibitors of S100A8 and/or S100A9 should also be 
tested in vivo. The effects of WIN55 should also be tested to determine if they are attenuated by 





CHAPTER 7: Summary and Future Direction 
 
Accumulating evidence indicates that synthetic or endogenous cannabinoids protect 
against central nervous system injury by factors including ischemia and reperfusion (200). Brain 
CB2 receptors are highly inducible; thus, under some pathological conditions (inflammation), 
CB2 expression is quickly enhanced (109). Di Filippo et al. demonstrate that treatment with the 
synthetic nonselective CB1/CB2 receptor agonist WIN55 significantly reduces the extent of 
myocardial infarct in mice suffering from myocardial IR injury; cardio protection is 
accompanied by lower myeloperoxidase activity and IL-1β and CXC chemokine ligand levels in 
injured tissue. This cardioprotective effect is almost abolished by the selective CB2 antagonist 
AM630, but it is not affected by the selective CB1 antagonist AM251 (200) (Fig 42). Although 
several rodent models have shown promising actions of cannabinoids on the cardiovascular 
system, we are a long way from seeing these compounds on the market (84). Selective CB1 
receptor antagonists were withdrawn from the market because of increased risk of depression 
(200).  
The effects of WIN55 were investigated initially in our rat model of CA and CPR. 
WIN55 was selected based on the following reasons: 1) the described hypothermia effect of CB1 
agonist is convincing and well documented, 2) it is highly selective for cannabinoid receptors 
and interacts negligibly with other neurotransmitter and ion channels (118), 3) it is expressed in 
thermoregulatory areas of the central nervous system and therefore decreases body temperature 





been demonstrated in both mice and rats that the CB2 receptor activation effects of WIN55 have 
significant anti-inflammatory effects (121-123). Our experimental CA/CPR (145, 162, 163) 
model indicates that local S100A8/A9 protein expression is increased within heart whole tissue 
lysates after CA and CPR.  We then confirmed WIN55 inhibited LPS induced expression of pro-
inflammatory cytokines in mouse RAW 264.7 macrophage cells. In vivo TNFα, IL6, and IL10 
plasma protein expression decreased at ROSC 4hrs with SR141716A+WIN55 treatment. Li et al 
recently report S100A8/A9 causes mitochondrial dysfunction via suppression of TLR4/ERK 
subsequent to mitochondrial complex I inhibition. S100A8/A9 is significantly upregulated 
during the early reperfusion stage (132). Mitochondria have emerged as central organelles that 
integrate metabolism and inflammatory responses (79). Therefore, future studies are necessary to 
determine if WIN55 could be a potential therapeutic to mitigate brain and heart damage after CA 
and CPR by blocking S100A8/A9 expression. We have determined brain mitochondria are more 
sensitive to global ischemia compared to heart mitochondria. Additionally, complex I is the most 
sensitive ETC complex to ischemic injury and its activity determines rate of OXPHOS following 
CA and RES. Preservation of brain mitochondrial activity and function during CA by inhibition 
of S100A8/A9 may enhance outcomes and recovery. For this reason, WIN55 could be a 
pharmacologic tool that preserves complex I activity during CA.  
The exact mechanism by which CB2 activation leads to anti-inflammatory effects and 
possible S100A8/A9 inhibition needs further investigation with macrophage in vitro studies and 
our experimental CA/CPR (145, 162, 163) model survival studies (Fig 43). Li et al report serum 





other points (132). We could then look at brain and heart mitochondria, local S100A8 histology 
and protein expression within the brain and heart along with systemic TNFα, IL6, IL10, cardiac 
troponin, and S100A8 plasma protein expression 24hrs and 48hrs after ROSC. 
 
Figure 58. Pathways of cannabinoid receptor-mediated protection against Ischemia 











Figure 59. Potential WIN55 inhibition of S100A8 and S100A9. Upon forming a heterodimer, 
S100A8/A9 is able to exert both intracellular and extracellular effects. Intracellularly, 
S100A8/A9 serves as a regulator of leukocyte transendothelial migration by promoting 
microtubule polymerization. It also promotes the downregulation of mitochondrial electron 
transport chain complex I and ATP production. Extracellularly, S100A8/A9 acts as a damage-
associated molecular pattern (DAMP) by binding to TLR4 receptors on phagocytes and 
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• Laboratory Management: I facilitated the radiation safety inspections and all applicable 
paperwork involved including monitoring of radioisotope levels and use and disposal of 
hazardous waste.  I also acted as the Chemical Hygiene Officer. I managed laboratory 
post award grant reconciliation between the Microbiology and Immunology Office, 
ordered supplies, maintained and performed troubleshooting on all laboratory equipment 
and supervised graduate students/hourly workers.  
• Bench Research: I observed and assisted with flow cytometry, western blotting, and real 






• Animal Research: I monitored the care of research animals and acted as a liaison with the 
IACUC office to ensure that all procedures were in compliance with IACUC and 
University regulations.  I also managed the mouse breeding colony of a myriad of 
knockout and transgenic strains. I conducted Flexivent procedures: non-survival surgery 
to investigate the effects of the house dust mite on various transgenic mouse models.   
 
Virginia Commonwealth University, Richmond, VA               July 2008 – February 2012 
Laboratory and Research Specialist I- Laboratory Specialist 
Department of Periodontics 
Principal Investigator: Dr. Harvey Schenkein 
Research Focus: Immunopathology of periodontal disease 
• Bench Research: I developed and modified protocols and carried out research 
independently- including tissue culture to isolate human blood cells for culture.  I ensured 
sterility, maintained and grew cell lines, and maintained anaerobic bacterial cultures 
without contamination. I also performed standard immunological assays such as 
separation of immune cells, prepared solutions, sterilized reagents and apparatus, and 
disposed of radioisotope equipment. 
• Animal Research: I gained extensive knowledge of breeding techniques and pregnant 
mouse/pup anatomy. 
 
Office of Laboratory Services, South Charleston, WV                          March 2007-July 2008 
Microbiologist I 
• Performed standardized bacteriologic and serologic examinations along with QC 
procedures for the state public health laboratory.   
• Carried out primary isolation techniques of microorganisms; prepared media, solutions, 
and reagents.  
• Operated laboratory equipment and/or scientific instrumentation for use in conducting 
diagnostic procedures, which included sterilization of apparatus.  
• Compiled and maintained records on the characteristics of the organisms identified.   
• Performed bacterial identification from patient cultures.   
• Operated gen probe (transcription-based amplification system).   
• Serotyped salmonella, shigella, e. coli, and meningitis isolated cultures.   
• Identified parasites using microscopy techniques on patient stool samples.   
• Processed sputum cultures to isolate tuberculosis.   
• Ensured proper immunohistochemistry-monoclonal antibody staining for the detection of 
rabies virus.   








West Virginia State Police, South Charleston, WV                      December 2006-March 2007 
Evidence Technician I 
Forensic Laboratory 
• Provided for the custody of all evidence submitted by various law enforcement agencies 
in West Virginia.   
• Maintained detailed records and integrity of evidence according to established laws, 
regulations, and standards. 
 
Publications 
Cheng C, Li H, Liang L, Jin T, Zhang G, Bradley JL, Peberdy MA, Ornato JP, Wijesinghe DS, 
Tang W. Effects of ω-3 PUFA and ascorbic acid combination on post-resuscitation myocardial 
function. Biomedicine and Pharmacotherapy. 2021;133:110970. 
Xiao, Y., Contaifer, D., Huang, W., Yang, J., Hu, Z., Guo, Q., Bradley, JL, Peberdy, M.A., 
Ornato JP, Wijesinghe, D., and Tang, W. Cannabinoid Receptor Agonist WIN55m212-2 Adjusts 
Lipid Metabolism in a Rat Model of Cardiac Arrest. Therapeutic Hypothermia and Temperature 
Management. 2020; doi: 10.1089/ther.2019.0038 
Ge, W., Zheng, G., Ji, X., He F., Hu, J., Bradley, JL, Moore C., Peberdy, MA, Ornato, JP, 
Mangino MJ, and Tang, W. Effects of Polyethylene Glycol-20k on Coronary Perfusion Pressure 
and Postresuscitation Myocardial and Cerebral Function in a Rat Model of Cardiac Arrest. J Am 
Heart Assoc. 2020;9:e014232 
Li H, Hua T, Wang W, Wu X, Miao C, Huang W, Xiao Y, Yang J, Bradley JL, Peberdy MA, 
Ornato J, Dix TA, Beck T, Tang W. The Effects of Pharmacological Hypothermia Induced by 
Neurotensin Receptor Agonist ABS 201 on Outcomes of CPR. Shock. 2019 May;51(5):667-673. 
doi: 10.1097/SHK.0000000000001178. 
Yang J, Xiao Y, Quan EY, Hu Z, Guo Q, Miao C, Bradley J, Peberdy MA, Ornato JP, and Tang 
W. Effects of Polyethylene Glycol-20k on Postresuscitation Myocardial and Cerebral Function in 
a Rat Model of Cardiopulmonary Resuscitation. Crit Care Med. 2018 Dec; 46(12):e1190-e1195 
Wang W, Hua T, Li H, Wu X, Bradley J, Peberdy MA, Ornato JP, and Tang W. Decreased 
cyclic adenosine monophosphate level and decreased downregulation of β1-adrenoceptor 
expression in therapeutic hypothermia resuscitated myocardium are associated with improved 
post-resuscitation myocardial function. J Am Heart Assoc. 2018 Mar 20;7(6):e006573 
Lu X, Fries M, Ravindra N, Bradley J, Peberdy MA, Ornato JP, Zhu CQ and Tang W. The 
Individual Role of Sarcolemmal and Mitochondrial KATP Channels Opening During 
Cardiopulmonary Resuscitation in a Porcine Model Treated with Levosimendan. Heart Circ 
2017; 1:017. 
Sun P, Wang J, Zhao S, Yang Z, Tang Z, Ravindra N, Bradley J, Ornato JP, Peberdy MA, Tang 
W. Improved Outcomes of Cardiopulmonary Resuscitation in Rats Treated with Vagus Nerve 
Stimulation and its Potential Mechanism. Shock 2017 Aug 9. [epub ahead of print] 
Miao C, Yang Z, Wen C, Yu T, Ravindra N, Bradley J, Peberdy MA, Ornato JP, and Tang W. 
Nitroglycerin Improves Microcirculation During and After Cardiopulmonary Resuscitation in a 





Hua T, Wu X, Wang W, Li H, Bradley J, Peberdy MA, Ornato JP, Tang W. Micro-and Macro 
Circulatory Changes During Sepsis and Septic Shock in a Rat Model. Shock 2017 Jul 20. [epub 
ahead of print] 
Rozycki HJ, Bradley J, KaramS. sRAGE is Elevated in the Lungs of Premature Infants 
Receiving Mechanical Ventilation. Am J Perinatol. March 2017 
Wang J, Wu X, Yan Z, Zhao S, QianJ, Yin L, Yu H, Gong P, Cahoon J, Bradley J, and Tang W. 
Protective Effects of Progesterone on Neurological outcomes in a Rat Model of Cardiac Arrest. 
Arch Emerg Med Crit Care December 2016 1 (3):1016 
Schenkein H.A, Bradley JL and Purkall D.B. Anticardiolipin in Porphyromonas gingivalis 
Antisera Causes Fetal Loss in Mice. Journal of Dental Research July 2013 92: 814-818 
 
Conferences  
Society of Critical Care Medicine Annual Congress 2020 
Wolf Creek Conference 2017, 2019, 2021 
American Thoracic Society International Conference 2013, 2014, 2015, and 2016 
American Association for Respiratory Care Conference 2013 
 
Grants and Scholarships 
 
2020-VCU Staff Senate Integrity Award $500 
2020-Graduate School Travel Grant $300 
2020-MPG CPC Travel Award $1,500 
2019-VCU Graduate School Hibbs/Waller Scholarship $1,000. 
2019-Jennifer Bradley, Mentor: Dr. Wanchun Tang, Measurement of systemic inflammatory 
response after administration of WIN55, 212-2. Zoll Foundation. $30,000. 
2018-MBG CPC Travel Award $180 
2018 Fall LabRoots Scholarship $2,000 
2017-2017-B Love of Learning Award from Phi Kappa Phi $500 
2015-Jennifer Bradley, Mentor: Dr. Bruce Rubin, Mature adipocytes from obese individuals 
release IL-13, which increases inflammation and induces a goblet cell phenotype in normal 
human bronchial epithelial (NHBE) cells at air-liquid interface (ALI). Children’s Hospital 
Foundation Research Fund. $5,000. 
 
Additional Training & Recognition  
 
VCU Training 
• Grace E Harris Leadership Institute 2020 class of the HIGHER Ground Women’s 
Leadership Development Program   
• Wright Center Grant Writing Course 





• Multiple Corporate Education Training courses (Leading Effective Teams, Maximizing 
Productivity and Managing and Leading Change) 
• SOM New Clinical Research Coordinator Boot Camp 
• Records Management 101 
 
Collaborative Institutional Training Initiative Course: 
  
• Faculty, Staff, and Students 
• Biomedical Responsible Conduct of Research  
• Good Clinical Practice 
• CITI Export Controls 
• Clinical Research Coordinator (CRC) 
 
American Association for Laboratory Animal Science: 
 
• Aseptic Technique for Rodent Survival Surgery 
• Introduction to Amphibians 
• Introduction to Ferrets 
• Introduction to Mice 
• Introduction to Rabbits 
• Introduction to Rats 
• Introduction to Swine 
• Mouse Breeding Colony Management 
• Post-procedure Care of Mice and Rats in Research Minimizing Pain and Distress 
• VCU Animal Research Facility Orientation Course 
• Working with the VCU IACUC for staff and students 
 
Other 
• Write Now Summer Session National Center for Faculty Development & Diversity 2020 
• Grantsmanship for Research Professionals 2020 
• RAMS Forum 2018, 2019, 2020 
• NCURA Sponsored Project Administration Workshop April and September 2019 
• Building Inclusive Communities June 2018 
• Bioinformatics 102 June 2018 
• Writing and Designing NIH Proposals Webinar February 2017 
• SBIR Webinar January 2017 
• NIH Grantsmanship Workshop January 2017 
• VCU Professional Development Certificate Program September 2016 to present 





• Dangerous Goods Shipping 
 




Member, Society of Critical Care Medicine 2018-present 
Member, American Association for the Advancement of Science 2018 




• Summer 2020. Mentor Karen Lo. VCU Medical Student Volunteer. 
• Summer 2020. Mentor Matthew Olocco. VCU Medical Student Volunteer. 
• Summer 2020. Mentor Hunter Hewlett. VCU Medical Student Volunteer. 
• 2019-2020. Mentor Chengli Su, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2019-2020. Mentor Yan Xiao, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Post-doctoral Scholar. 
• 2019-2020. Mentor Guozhen Zhang, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2019-2020. Mentor Jin Tao, MD. Weil Institute of Emergency and Critical Care Research 
Visiting Fellow. 
• 2019-2020. Mentor Cheng Cheng, MD, PhD. Weil Institute of Emergency and Critical 
Care Research Visiting Fellow. 
• 2019-2020. Mentor Hui Li, MD. Weil Institute of Emergency and Critical Care Research 
Visiting Fellow. 
• 2019-2020. Mentor Lian Liang, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• Summer 2019. Mentor Iris Huang. High School Student Volunteer. 
• Summer 2019. Mentor Liuzhi Zhang. VCU Medical Student Volunteer. 
• Summer 2019. Mentor Lazar Jankovic. VCU Medical Student Volunteer. 
• Summer 2019. Mentor Helen Mai. VCU Undergraduate Student Volunteer. 
• Summer 2019. Mentor Esha Sharma. Godwin High School Student Volunteer Intern. 
• Summer 2019. Mentor Devi Veeramgari. Godwin High School Student Volunteer Intern. 
• Summer 2019. Mentor Aaron Yuan. Godwin High School Student Volunteer. 
• 2018-2019. Mentor Fenglian He, MD, PhD. Weil Institute of Emergency and Critical 
Care Research Visiting Fellow. 
• 2018-2019. Mentor Juntao Hu, MD. Weil Institute of Emergency and Critical Care 





• 2018-2019. Mentor Xianfei Ji, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2018-2019. Mentor Weiwei Ge, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2018-2019. Mentor Guanghui Zheng, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• Summer 2018. Clairice Dailey. Weil Institute of Emergency and Critical Care Research 
Volunteer. 
• 2017-2018. Mentor Jing Xu, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2017-2018 Mentor Chang-Sheng Wang, MD, PhD. Weil Institute of Emergency and 
Critical Care Research Visiting Fellow. 
• 2017-2018. Mentor Qinyue Guo, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2017-2018. Mentor Zhangle Hu, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• Summer 2017. Nikki Duggal. Weil Institute of Emergency and Critical Care Research 
Volunteer. 
• 2016-2017. Mentor Changqing Miao, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2016-2017. Mentor Jin Yang, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2016-2017. Mentor Tianfeng Hua, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2016-2017. Mentor Weiping Huang, MD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2016-2017. Mentor Yan Xiao, MD, PhD. Weil Institute of Emergency and Critical Care 
Research Visiting Fellow. 
• 2014-2017. Navami Ravindra BS Biomedical Engineering. Weil Institute of Emergency 
and Critical Care Research and Department of Pediatrics Volunteer. 
• 2014-2016. Mentor Tomohiro Akaba, MD, PhD. Department of Pediatrics Postdoctoral 
Scholar. 
• 2014-2016. Mentor Kosaku Komiya, MD, PhD. Department of Pediatrics Postdoctoral 
Scholar. 
• 2014-2016. Mentor Jonathan Ma, MD. Department of Pediatrics Pediatric Resident. 
• 2014-2016. Mentor Ashleigh McCormick. Department Biomedical Engineering, 
Undergraduate Researcher. 










Graduate Student Rep, SOM Teaching Awards Selection Committee  Summer 2020 and 2019 
Volunteer Judge, Virginia Junior Sciences and Humanities Symposium (JSHS)      March 2020                                                                                                                                          
Volunteer, Medical Reserve Corps                                                         September 2008-Present 
Volunteer, Emergency Department at MCV                                         Spring and Summer 2013 
Mentor, Tutor of Education and Living Skills                                          August 2002-May 2006 
Volunteer, Health Clinic in Ayacucho, Peru                                                             Summer 2004 
 
 
 
